Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 10124. Отображено 100.
05-01-2012 дата публикации

Bone-like prosthetic implants

Номер: US20120003185A1
Автор: Shai Meretzki
Принадлежит: Individual

A prosthetic implant comprising a biocompatible three-dimensional scaffold and at least two cell types selected from the group consisting of osteoblasts, osteoclasts, and endothelial cells or progenitors thereof.

Подробнее
26-01-2012 дата публикации

Thermosensitive hydrogel composition and method

Номер: US20120020932A1
Принадлежит: Zimmer Orthobiologics Inc

A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.

Подробнее
02-02-2012 дата публикации

Method of preparing lipid nanoparticles

Номер: US20120027825A1

The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain nanocapsules comprising said hydrophilic active agent and being formed from a lipid core, which is liquid at room temperature, and encapsulated in a film which is solid at room temperature. Further, the invention relates to nanocapsules which are able to be obtained by said method.

Подробнее
01-03-2012 дата публикации

Composition and a method for producing contrast agent using the composition

Номер: US20120052011A1
Принадлежит: Canon Inc

A composition including a hydrophilic dye having a sulfonate group and a hydrophobic solvent, wherein the composition includes at least one of a nicotinic acid derivative and a tiamine derivative, can form densely accumulated particles and the like since the composition includes a hydrophilic dye that is likely to dissolve in a hydrophobic solvent.

Подробнее
15-03-2012 дата публикации

siRNA Targeting Apolipoprotein B (APOB)

Номер: US20120065250A1
Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.

Подробнее
03-05-2012 дата публикации

Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference

Номер: US20120107389A1
Принадлежит: Individual

The present invention provides method and pharmaceutical composition for efficient delivery of siRNA (small interfering ribonucleic acids) into cultured mammalian cells. In addition, the present invention provides methods and compositions for knocking down the expression of a specific target gene by treating cells with the formulations comprising cationic amphiphile, a neutral colipid and a small RNA molecule. We demonstrate that our method delivers siRNA efficaciously into animal cells for the purpose of RNA interference. The area of medical science that is likely to benefit most from the present invention is RNAi therapeutics.

Подробнее
17-05-2012 дата публикации

No-Carrier-Added Nucleophilic [F-18] Fluorination of Aromatic Compounds

Номер: US20120123120A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Phenyliodonium ylide derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are shown for use as precursors in aromatic nucleophilic substitution reactions. The iodonium ylide group is substituted by nucleophiles such as halide ions to provide the corresponding haloaryl derivatives. No-carrier-added [F-18]fluoride ion exclusively substitutes the iodonium ylide moiety in these derivatives and provides high specific activity F-18 labeled fluoro derivatives. Protected L-dopa-6-iodonium ylide derivative have been synthesized as a precursors for the preparation of no-carrier-added 6-[F-18]fluoro-L-dopa. The iodonium ylide group in this L-dopa.derivative is nucleophilically substituted by no-carrier-added [F-18]fluoride ion to provide a [F-18]fluoro intermediates which upon acid hydrolysis yielded 6-[F-18]fluoro-L-dopa.

Подробнее
24-05-2012 дата публикации

Method of preparing pluripotent stem cells

Номер: US20120129256A1

The invention relates to biotechnology, and particularly to the preparation of pluripotent stem cells. The method involves introduction into umbilical cord and placental stem cells of RNA with at least one sequence which ensures the transition of cells to the pluripotent state. The method enables to effectively prepare pluripotent stem cells from the cells of mammalian placenta and umbilical cord which have not yet acquired somatic mutations, which reduces the risk of oncogenesis and other adverse effects of reprogramming.

Подробнее
23-08-2012 дата публикации

Generating induced pluripotent stem cells and progenitor cells from fibroblasts

Номер: US20120214236A1
Принадлежит: MCMASTER UNIVERSITY

The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.

Подробнее
18-10-2012 дата публикации

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

Номер: US20120264736A1
Принадлежит: Schering Corp

This invention discloses novel gamma secretase inhibitors of the formula: R 2 and R 3 , or R 2 and R 4 , or R 3 and R 4 , together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Подробнее
25-10-2012 дата публикации

Co-crystal of 4-furan-2(5h)-one with oxalic acid and use thereof as pesticide

Номер: US20120270904A1
Принадлежит: BAYER TECHNOLOGY SERVICES GMBH

The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one with oxalic acid, and also to processes for preparation thereof and use.

Подробнее
25-10-2012 дата публикации

siRNA Targeting Apoliprotein (APOB)

Номер: US20120270926A1
Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.

Подробнее
22-11-2012 дата публикации

Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug

Номер: US20120295855A1

The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.

Подробнее
20-12-2012 дата публикации

Cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation

Номер: US20120322755A1
Принадлежит: INSTYTUT CHEMII BIOORGANICZNEJ PAN

This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. More precisely, the invention relates to various derivatives of cytosine, as well as methods of preparation of mono- and multi-1,4,5 and 6-substituted cytosines. In general, the solution relates to providing effective modulators of DNA methylation which could be used in prevention and treatment of diseases associated with DNA methylation level disorders.

Подробнее
17-01-2013 дата публикации

Orally administered agent and an orally administered agent/supporting substrate complex

Номер: US20130017235A1
Автор: Eiji Nogami
Принадлежит: Lintec Corp

With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1 b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Подробнее
07-03-2013 дата публикации

Induced pluripotent stem cells produced with oct3/4, klf and sox

Номер: US20130059386A1
Принадлежит: KYOTO UNIVERSITY

The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.

Подробнее
21-03-2013 дата публикации

EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME

Номер: US20130072683A1
Принадлежит: OTSUKA PHARMACEUTICAL CO., LTD.

The present invention provides a novel intermediate for manufacturing a 2,3-dihydroimidazo[2,1-b]oxazole compound with a high yield and a high purity, and a manufacturing method of the intermediate. The present invention provides an epoxy compound represented by the general formula (2): wherein, R1 represents a hydrogen or a lower alkyl group; and R2 represents a piperidyl group represented by the general formula (A1): (wherein, R3 represents a phenoxy group having a halogen-substituted lower alkoxy group substituted on a phenyl group, and the like) and the like; and n represents an integer of 1 to 6, a manufacturing method of the epoxy compound, and a manufacturing method of an oxazole compound using the epoxy method. 2. An epoxy compound or salts thereof selected from the group consisting of:1) (R)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]-4-(4-trifluoromethoxyphenoxy)piperidine;2) (R)-1-[4-(2,3-epoxypropoxy)phenyl]-4-(4-trifluoromethoxyphenoxy)piperidine;3) (R)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]-4-(4-trifluoromethylphenoxymethyl)piperidine;4) (R)-1-[4-(2,3-epoxypropoxy)phenyl]-4-(4-trifluoromethylphenoxymethyl)piperidine;5) (R)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]-4-[3-(4-trifluoromethoxyphenyl)-2-propenyl]piperazine;6) (R)-1-[4-(2,3-epoxypropoxy)phenyl]-4-[3-(4-trifluoromethoxyphenyl)-2-propenyl]piperazine;7) (R)-4-(4-chlorobenzyloxymethyl)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]piperidine;8) (R)-4-(4-chlorobenzyloxymethyl)-1-[4-(2,3-epoxypropoxy)phenyl]piperidine;9) (R)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]-4-(4-trifluoromethoxybenzyl)piperidine;10) (R)-1-[4-(2,3-epoxypropoxy)phenyl]-4-(4-trifluoromethoxybenzyl)piperidine;11) (R)-1-[4-(2,3-epoxy-2-methylpropoxy)phenyl]-4-[N-methyl-N-(4-trifluoromethoxyphenyl)]aminopiperidine;12) (R)-4-[N-methyl-N-(4-trifluoromethoxyphenyl)]amino-1-[4-(2,3-epoxypropoxy)phenyl]piperidine;13) (R)-1-(4-chlorophenyl)-4-[4-(2,3-epoxy-2-methylpropoxy)phenyl]piperazine;14) (R)-1-(4-chlorophenyl)-4-[4-(2,3-epoxypropoxy)phenyl] ...

Подробнее
04-04-2013 дата публикации

SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

Номер: US20130085158A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith. 1. A solid form of 3-(6-(1-(2 ,2-Difluorobenzo[d][1 ,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) , characterized as Compound 1 , Solvate Form A or Compound 1 , HCl Salt Form A.2. Compound 1 claim 1 , Solvate Form A of claim 1 , wherein Compound 1 claim 1 , Solvate Form A is characterized as a crystalline lattice of Compound 1 containing a plurality of repeating cavities which are empty or at least partially occupied by a solvate.3. Compound 1 claim 1 , Solvate Form A of claim 1 , wherein Compound 1 claim 1 , Solvate Form A is characterized as a crystalline lattice of Compound 1 containing a plurality of repeating cavities claim 1 , wherein a plurality of the cavities are empty.4. Compound 1 claim 1 , Solvate Form A of claim 1 , characterized by one or more peaks at 21.5 to 21.9 degrees claim 1 , 8.8 to 9.2 degrees claim 1 , and 10.8 to 11.2 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.5. Compound 1 claim 1 , Solvate Form A of claim 1 , characterized by one or more peaks at 21.5 to 21.9 degrees claim 1 , 8.8 to 9.2 degrees claim 1 , 10.8 to 11.2 degrees claim 1 , 18.0 to 18.4 degrees claim 1 , and 22.9 to 23.3 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.6. Compound 1 claim 1 , Solvate Form A of claim 1 , characterized by one or more peaks at 21.70 claim 1 , 8.98 claim 1 , 11.04 claim 1 , 18.16 claim 1 , and 23.06 degrees.7. Compound 1 claim 1 , Solvate Form A of claim 1 , characterized by a peak at 21.5 to 21.9 degrees.8. Compound 1 claim 1 , Solvate Form A of claim 1 , characterized by a peak at 21.70 degrees.9. Compound 1 claim 8 , ...

Подробнее
18-04-2013 дата публикации

POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS

Номер: US20130095035A1
Принадлежит: MIVENION GMBH

The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations. 1. Pharmaceutical composition comprising a sulfated polyglycerol and a therapeutic or diagnostic effector molecule that is covalently conjugated to said sulfated polyglycerol.2. Pharmaceutical composition according to of the formula P(OSOM)(L-G-E)with P is a polyol macromolecule wherein a number n of hydroxyl groups is substituted by sulfate groups OSOM claim 1 , M is a cationic inorganic or organic counter ion to the anionic sulfate group claim 1 , E is therapeutic or diagnostic effector molecule claim 1 , L is a linker or spacer between P and E claim 1 , G is a reactive group for the covalent attachment between L and E claim 1 , and m is a number of 1-100.3. Pharmaceutical composition according to for treating a disease by intracellular uptake of said sulfated polyglycerol and a therapeutic or diagnostic effector molecule into activated cells or proliferative cells and by inhibiting NF-kappaB and/or AP-1 and/or inhibiting TGF-beta synthesis in said cells.4. Conjugate comprising a sulfated polyglycerol and a therapeutic or diagnostic effector molecule that is covalently conjugated to said sulfated polyglycerol.5. Conjugate according to of the formula P(OSOM)(L-G-E)with P is a polyol macromolecule wherein a number n of hydroxyl groups is substituted by sulfate groups OSOM claim 4 , M is a cationic inorganic or organic counter ion to the anionic sulfate group claim 4 , E is therapeutic or diagnostic effector molecule claim 4 , L is a linker or spacer between P and E claim 4 , G is a reactive group for the ...

Подробнее
25-04-2013 дата публикации

Method of manufacturing display apparatus

Номер: US20130100386A1
Принадлежит: SAMSUNG ELECTRONICS CO LTD

In a method of manufacturing a display apparatus, a first substrate including a plurality of pixels is formed, and a black column spacer is formed on the first substrate. A second substrate is formed, and a liquid crystal layer is formed between the first substrate and the second substrate. The black column spacer is formed by coating a photoresist on the first substrate, exposing the photoresist to a first light, developing the exposed photoresist and exposing the developed photoresist to a second light.

Подробнее
25-04-2013 дата публикации

FUNGICIDE N-CYCLOALKYL-N-BICYCLIMETHYLENE-CARBOXAMIDE DERIVATIVES

Номер: US20130102790A1
Принадлежит:

The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Zrepresents a C-C-cycloalkyl group, X represents N or a CZand Y, Y, Z, Z, Land Lrepresent various substituents. Their process of preparation, the preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions are also disclosed. 118-. (canceled)20. The compound of wherein Yis C-C-alkyl and Yis hydrogen.21. The compound of wherein Yis methyl.22. The compound of wherein Yand Yare both C-C-alkyl.23. The compound of wherein Yand Yare both methyl.24. The compound of wherein Zis hydrogen.25. The compound of wherein Lis CZZ.26. The compound of wherein Lis CZZand m is 1 or 2.27. The compound of wherein Zand each Zare independently selected from the group consisting of a hydrogen atom claim 19 , a halogen atom claim 19 , C-C-alkyl claim 19 , C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different claim 19 , C-C-alkoxy claim 19 , and C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different.28. The compound of wherein said compound is N-cyclopropyl-3-(difluoromethyl)-N-[1-(1-hydroxy-1 claim 19 ,2 claim 19 ,3 claim 19 ,4-tetrahydronaphthalen-1-yl)ethyl]-1-methyl-1H-pyrazole-4-carboxamide. The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide or thiocarboxamide derivatives, their process of preparation, preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.In international patent application WO2007060164 ...

Подробнее
02-05-2013 дата публикации

HAPTEN CONJUGATES FOR TARGET DETECTION

Номер: US20130109019A1
Принадлежит:

Embodiments of hapten conjugates including a hapten, an optional linker, and a peroxidase-activatable aryl moiety are disclosed. In some embodiments, the peroxidase-activatable aryl moiety is tyramine or a tyramine derivative. Embodiments of methods for making and using the hapten conjugates also are disclosed. In particular embodiments, the hapten conjugates are used in a signal amplification assay. In certain embodiments, the hapten is an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, or 7-diethylamino-3-carboxycoumarin. The hapten is coupled to the peroxidase-activatable aryl moiety directly or indirectly via a linker. In certain embodiments, the hapten conjugates are used in multiplexed assays. 1. A hapten conjugate , comprising:a hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, 2,3,6,7-tetrahydro-11-oxo-1H,5H,11H-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic acid, or 7-diethylamino-3-carboxycoumarin;a linker; anda tyramine or a tyramine derivative.2. (canceled)6. (canceled)811.-. (canceled)1332.-. (canceled)33. A method , comprising:(a) immobilizing a first peroxidase on a first target in a sample, wherein the first peroxidase is capable of reacting with a peroxidase-activatable aryl moiety;(b) contacting the sample with a solution comprising a first hapten conjugate, the first hapten conjugate comprising a first hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an ...

Подробнее
02-05-2013 дата публикации

QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS

Номер: US20130109706A1

Quinazoline derivatives are provided that specifically inhibit proliferation of T cells without affecting the level of IL-2 secreted from said T cells. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of indications mediated by T cell proliferation. 2. The compound of claim 1 , wherein Ris 3 claim 1 ,4 claim 1 ,5-trimethoxyphenyl or 3 claim 1 ,4 claim 1 ,5-trihydroxyphenyl.3. The compound of claim 2 , wherein Ris 3 claim 2 ,4 claim 2 ,5-trimethoxyphenyl and Ris 4-methylphenyl (herein identified compound 2).4. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , and a pharmaceutically acceptable carrier.5. (canceled)6. A topical composition according to .7. (canceled)8. (canceled)10. The method of claim 9 , wherein Ris phenyl substituted by 1 to 5 claim 9 , —ORgroups; and Reach is H or (C-C).11. The method of claim 10 , wherein Ris phenyl substituted at each one of positions 3 claim 10 , 4 and 5 by —ORgroup wherein Ris H or methyl.12. The method of claim 9 , wherein Ris —(CH)—heteroaryl claim 9 , or —(CH)-phenyl substituted by one or more groups each independently selected from the group consisting of F claim 9 , Cl claim 9 , (C-C)alkyl claim 9 , (C-C)alkylene-OH claim 9 , —NH claim 9 , —O—(CH)—C(Hal) claim 9 , and —OR claim 9 , wherein Ris H claim 9 , methyl or ethyl claim 9 , or two —ORgroups linked to two adjacent carbon atoms of said aryl claim 9 , together with the carbon atoms to which they are attached claim 9 , form 1 claim 9 ,3-dioxolane ring or 1 claim 9 ,4-dioxane ring.13. The method of claim 12 , wherein Ris selected from the group consisting of phenyl claim 12 , 4-methylphenyl claim 12 , 2 claim 12 ,4-dimethylphenyl claim 12 , 4-hydroxyphenyl claim 12 , 4-methoxyphenyl claim 12 , 4-octyloxyphenyl claim 12 , 4-trifluoromethoxyphenyl claim 12 , 4-chlorophenyl claim 12 , 2-hydroxymethylphenyl claim 12 , benzyl claim 12 , ...

Подробнее
09-05-2013 дата публикации

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Номер: US20130116232A1
Принадлежит: ARAGON PHARMACEUTICALS, INC.

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': '1', 'sub': 1', '4, 'Ris C-Calkyl;'}{'sup': 2a', '2b, 'Rand Rare taken together with the N atom to which they are attached to form a substituted or unsubstituted monocyclic heterocycloalkyl, a substituted or unsubstituted bicyclic heterocycloalkyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl;'}{'sup': '3', 'sub': 1', '4', '1', '4, 'Ris C-Calkyl or C-Cfluoroalkyl;'}{'sup': 4', '9', '9', '10', '10, 'sub': 2', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'each Ris independently selected from H, halogen, —CN, —OH, —OR, —SR, —S(═O)R, —S(═O)R, C-Calkyl, C-Cfluoroalkyl, C-Cfluoroalkoxy, C-Calkoxy, and C-Cheteroalkyl;'}{'sup': 5', '9, 'sub': 1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'each Ris independently selected from H, halogen, —CN, —OH, —OR, C-Calkyl, C-Cfluoroalkyl, C-Cfluoroalkoxy, C-Calkoxy, and C-Cheteroalkyl;'}{'sup': '6', 'sub': 1', '6', '1', '6', 'r', '6', '1', '6, 'each Ris independently selected from H, halogen, —CN, —OH, C-Calkyl, C-Cfluoroalkyl, CCfluoroalkoxy, and C-Calkoxy;'}{'sup': '7', 'sub': '3', 'Ris H or —CH;'}Y is —O— or —S—.46-. (canceled)7. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein:{'sup': '1', 'sub': '3', 'Ris —CH;'}{'sup': '3', 'sub': 3', '3, 'Ris —CHor —CF;'}{'sup': 2a', '2b, 'Rand Rare taken together with the N atom to which they are attached to form a substituted or unsubstituted pyrrolidinyl;'}X is —O—;Y is —O—.8. (canceled)11. (canceled)13. The compound ...

Подробнее
09-05-2013 дата публикации

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Номер: US20130116238A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 2. The compound of of formula I claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , and Ris F.3. The compound of of formula I claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , Ris F claim 1 , and Ris CH.4. The compound of of formula I claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , Ris F claim 1 , Ris CH claim 1 , and X is COH.5. The compound of of formula I claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , Ris F claim 1 , Ris CH claim 1 , X is COH claim 1 , and Y is OH.6. The compound of of formula II claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , and Ris F.7. The compound of of formula II claim 1 , wherein two R taken together form —OCFO— claim 1 , Ris H claim 1 , Ris F claim 1 , and Ris CH.9. The compound of claim 8 , wherein Ris F.13. A pharmaceutical composition comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) a compound according to ; and'}(ii) a pharmaceutically acceptable carrier.14. The composition of claim 13 , further comprising an additional agent selected from a mucolytic agent claim 13 , bronchodialator claim 13 , an anti-biotic claim 13 , an anti-infective agent claim 13 , an anti-inflammatory agent claim 13 , CFTR corrector claim 13 , CFTR potentiator claim 13 , or a nutritional agent.15. A method of increasing the number of functional ABC transporters in a membrane of a cell claim 1 , comprising the step of contacting the cell with a compound of .16. The method of claim 15 , wherein the ABC transporter is CFTR.17. A ...

Подробнее
16-05-2013 дата публикации

NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF

Номер: US20130123269A1
Автор: Li Peng
Принадлежит: INTRA-CELLULAR THERAPIES, INC.

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): 123-. (canceled)25. The method of treatment according to claim 24 , wherein the neurodegenerative disease is characterized as the accumulation of abnormal protein aggregates in the brain.26. The method of treatment according to claim 25 , wherein the neurodegenerative disease characterized by the accumulation of abnormal protein aggregates in the brain is selected from the group consisting of: Alzheimer's disease claim 25 , progressive supranuclear palsy claim 25 , Down Syndrome claim 25 , memory and cognitive disorders claim 25 , dementia claim 25 , amyloid neuropathies claim 25 , brain inflammation claim 25 , nerve and brain trauma claim 25 , vascular amyloidosis claim 25 , cerebral hemorrhage with amyloidosis claim 25 , Parkinson's disease claim 25 , Huntington's disease claim 25 , prion disease and vascular claim 25 , neurological claim 25 , neurodegenerative disorders related to the abnormal expression or accumulation of tau or amyloid proteins.27. The method of treatment according to claim 26 , wherein the abnormal protein aggregates are selected from the group consisting of: amyloid plaques claim 26 , neurofibrillary tangles claim 26 , and precipitates of tau or amyloid proteins.28. The method of treatment according to claim 24 , wherein the hyperproliferative disease is a cancer of the brain or central nervous system.29. The method of treatment according to claim 28 , wherein the cancer of the brain or central nervous system is selected from the group consisting of: astrocytoma claim 28 , medulloblastoma claim 28 , oligdendroglioma claim 28 , glioblastoma claim 28 , glioma claim 28 , ependymoma claim 28 , meningioma claim 28 , sarcoma claim 28 , germ cell tumor claim 28 , pinealoma claim 28 , craniopharyngioma claim 28 , and pituitary adenoma.30. The method of treatment according to claim 26 , wherein the compound according to formula I is ...

Подробнее
16-05-2013 дата публикации

Bioassay for gene silencing constructs

Номер: US20130125260A1
Принадлежит: Venganza Inc

The invention provides constructs and methods of screening for constructs useful in conferring resistance in plants to pests by gene silencing. The invention also provides pest-resistant plants transformed with the present constructs. One screening method of the invention comprises the steps of: selecting at least one pest target nucleotide sequence, producing a plurality of dsRNA test agents that target the pest target nucleotide sequence, testing and scoring the plurality of dsRNA test agents for toxicity to the pest, and producing a silencing construct based on a superior-scoring test agent.

Подробнее
23-05-2013 дата публикации

Human Stem Cell Materials and Methods

Номер: US20130129696A1
Принадлежит: Individual

Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals is provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof The uses of these biological materials include methods of treating disorders or diseases, as well as methods of ameliorating a symptom associated with any such disorder or disease.

Подробнее
23-05-2013 дата публикации

NEW COMPOUNDS

Номер: US20130131075A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to the compounds of general formula I 2. A compound of the formula I according to claim 1 , wherein:{'sup': '1', 'claim-text': [{'sub': '1-6', 'sup': '1.1', '(a) a C-alkyl group optionally substituted by a group R,'}, {'sub': '1-3', '(b) a C-alkyl group wherein each methylene group may be substituted by 1 or 2 fluorine atoms and each methyl group may be substituted by 1, 2 or 3 fluorine atoms,'}, {'sub': 3-6', '2, 'sup': '1.2', '(c) a C-cycloalkyl group optionally substituted by a group Rwherein a —CH-unit may be replaced by a —C(O)— group,'}, {'sup': '1.3', '(d) a phenyl group optionally substituted by 1, 2 or 3 groups R,'}, {'sup': '1.4', '(e) a five-membered heteroaryl group optionally substituted by 1, 2 or 3 groups R, which contains at least one N, O or S atom and which optionally additionally contains one, two or three further N-atoms,'}, {'sup': '1.4', '(f) a six-membered heteroaryl group optionally substituted by 1 or 2 groups R, which contains one, two or three N-atoms,'}, {'sup': '1.4', '(g) a nine- or ten-membered heteroaryl group optionally substituted by 1 or 2 groups R, which contains one, two or three N-atoms,'}, {'sup': '1.4', 'sub': '2', '(h) a 5- or 6-membered heterocyclic group optionally substituted by 1 or 2 groups R, in which a —CH— unit may be replaced by a —C(O)— group,'}, {'sup': '1.1.1', '(i) —O—Ror'}, {'sup': 1.1.3', '1.1.4, '(j) —NRR,'}], 'Rdenotes'}{'sup': 1.1', '1.1.1', '1.1.3', '1.1.4, 'sub': '3-6', 'Rdenotes —CN, C-cycloalkyl, —OR, NRR,'}{'sup': '1.1.1', 'claim-text': (a) H,', {'sub': '1-4', '(b) C-alkyl,'}, {'sub': '1-3', '(c) a C-alkyl group wherein each methylene group may be substituted by 1 or 2 fluorine atoms and each methyl group may be substituted by 1, 2 or 3 fluorine atoms,'}], 'Rdenotes'}{'sup': '1.1.3', 'R,'}{'sup': '1.1.4', 'claim-text': (a) H,', {'sub': '1-4', '(b) C-alkyl,'}, {'sub': '3-6', '(c) C-cycloalkyl, or'}], 'Rindependently of one another denote'}{'sup': 1.1.3', '1.1.4, 'Rand ...

Подробнее
23-05-2013 дата публикации

Flufenoxine derivatives for the treatment and prevention of amyloid pathologies

Номер: US20130131079A1
Принадлежит: Faes Farma SA

The present invention is directed to a compound of formula (I) for use in a method to treat or ameliorate amyloid or tau pathologies, such as Alzheimer's disease, or symptoms thereof. The invention is also directed to new compounds of formula (I), of subformula (II), (III), (IV), or (V).

Подробнее
06-06-2013 дата публикации

COMPOSITION COMPRISING TETRACYCLIC COMPOUND

Номер: US20130143877A1
Принадлежит:

A composition which comprises substance represented by Formula (I), 2. The composition according to claim 1 , wherein said dissolution aid is a surfactant.3. The composition according to claim 2 , wherein said surfactant is a non-ionic or an anionic surfactant.4. The composition according to claim 2 , wherein said surfactant is selected from a group consisting of monoalkyl sulfate claim 2 , polyoxyl 40 stearate claim 2 , sorbitan trioleate claim 2 , polyoxyethylene (105) polyoxypropylene (5) glycol claim 2 , polyoxyethylene hydrogenated castor oil 60 claim 2 , polyoxyl 35 castor oil claim 2 , lauromacrogol claim 2 , dioctyl sodium sulfosuccinate claim 2 , sodium lauroylsarcosine claim 2 , sodium dodecylbenzene sulfonate claim 2 , and a mixture thereof.5. The composition according to claim 2 , wherein said composition further comprises an organic polymer.6. The composition according to claim 5 , wherein said organic polymer is selected from a group consisting of a synthetic resin claim 5 , a water soluble polymer claim 5 , a gastric-soluble polymer claim 5 , an enteric-soluble polymer claim 5 , and a mixture thereof.7. The composition according to claim 5 , wherein said organic polymer is a synthetic resin.8. The composition according to claim 2 , wherein said composition further comprises one or more additives which are selected from the following additive group A:additive A: citric acid, fumaric acid, DL-malic acid, adipic acid, succinic acid, tartaric acid, lactic acid, maleic acid, sulfuric acid, phosphoric acid, sodium dehydroacetate, sodium stearyl fumarate, stearic L-ascorbate ester, L-aspartic acid, skimmed milk powder, aluminum lactate, ascorbic acid palmitate, aluminum sulfate, monobasic calcium phosphate, or acetyl tryptophan.9. The composition according to claim 1 , wherein said water solubility of the substance is less than 100 μg/mL at 25° C.10. The composition according to claim 1 , wherein Ato A claim 1 , A claim 1 , and Aare a carbon atom claim 1 , ...

Подробнее
06-06-2013 дата публикации

Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide

Номер: US20130143918A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.

Подробнее
20-06-2013 дата публикации

Hsp70 fusion protein conjugates and uses thereof

Номер: US20130156694A1
Принадлежит: Alternative Innovative Tech LLC

The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.

Подробнее
11-07-2013 дата публикации

Process for preparation of substantially pure fosamprenavir calcium and its intermediates

Номер: US20130174651A1
Принадлежит: Lupin Ltd

The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.

Подробнее
11-07-2013 дата публикации

Novel Benzopyran Compounds, Compositions and Uses Thereof

Номер: US20130178445A1
Принадлежит: OLEMA PHARMACEUTICALS, INC.

Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans. 5. The compound of wherein the salt is pharmaceutically acceptable.6. The compound of wherein the salt is pharmaceutically acceptable.7. The compound of which is not in the form of a salt.8. The compound of which is not in the form of a salt.11. The compound of claim 9 , wherein Rand Rare —OR.12. The compound of claim 10 , wherein Rand Rare —OR.13. The compound of claim 9 , wherein Ris hydrogen.14. The compound of claim 10 , wherein Ris hydrogen.15. The compound of claim 11 , wherein —ORis C(O)alkyl.16. The compound of claim 12 , wherein —ORis C(O)alkyl17. The compound of claim 11 , wherein —ORis C(O)aryl.18. The compound of claim 12 , wherein —ORis C(O)aryl.19. The compound of claim 11 , wherein —ORis OPOH.20. The compound of claim 12 , wherein —ORis OPOH.23. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of in a pharmaceutically acceptable carrier.24. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of in a pharmaceutically acceptable carrier.2519. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 2 , claim 2 , claim 2 , claim 2 , claim 2 , claim 2 , claim 2 , claim 2 , or in a pharmaceutically acceptable carrier.26. A pharmaceutical composition comprising a pharmaceutically ...

Подробнее
25-07-2013 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION

Номер: US20130190296A1
Принадлежит: Dendreon Corporation

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Tip-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression. 24.-. (canceled)5. A composition comprising a compound of and a pharmaceutically acceptable excipient or diluent.67.-. (canceled)8. A method for decreasing the viability of a Trp-p8 expressing cell claim 1 , said method comprising the step of contacting said cell with a small-molecule Trp-p8 modulator in a concentration and for a time required to decrease the viability of said cell.9. The method of wherein said small-molecule Trp-p8 modulator is selected from the group consisting of a compound of Formula I claim 8 , a compound of Formula II claim 8 , a compound of Formula III claim 8 , a compound of Formula IV claim 8 , a compound of Formula V claim 8 , a compound of Formula VI claim 8 , a compound of Formula VII claim 8 , and a compound of Formula VIII.1417-. (canceled)19. (canceled)22. A method for inducing apoptosis and/or necrosis in a cell expressing Trp-p8 or for treating a disease associate with Trp-p8 expression claim 8 , said method comprising the step of administering to said cell a small-molecule Trp-p8 modulator selected from the group consisting of a compound of Formula I claim 8 , a compound of Formula II claim 8 , a compound of Formula III claim 8 , a compound of Formula IV claim 8 , a compound of Formula V claim 8 , a compound of Formula VI claim 8 , a compound of Formula VII claim 8 , ...

Подробнее
01-08-2013 дата публикации

ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND

Номер: US20130196434A1
Принадлежит: Alnylam Pharmaceuticals Inc

One aspect of the present invention relates to a double stranded nucleic acid useful as an siRNA, that has a sense strand and an antisense strand relative to a target nucleic acid, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one nucleoside comprising a non-natural nucleobase. Another aspect of the invention relates to a method of gene silencing, comprising administering to a mammal in need thereof a therapeutically effective amount of a double-stranded oligonucleotides containing a sense strand and an antisense strand, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand.

Подробнее
01-08-2013 дата публикации

MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

Номер: US20130196987A1
Принадлежит: EISAI CO., LTD.

The present invention provides compounds, methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. 2. (canceled)3. The compound of claim 1 , wherein:{'sub': 1', '1-6', '1-6, 'Ris hydrogen, straight or branched Calkyl, straight or branched Cheteroalkyl, or aryl,'}wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; and{'sub': '3', 'Ris hydrogen.'}4. The compound of claim 3 , where X is oxygen.5. (canceled)6. The compound of claim 3 , where Ris hydrogen.7. The compound of claim 3 , where Y and Z together represent —CH═CH—.8. The compound of claim 3 , where Y and Z together represent trans —CH═CH—.10126-. (canceled)127. The compound of claim 9 , wherein X is oxygen claim 9 , Ris hydrogen and Y and Z together represent —CH═CH—.130. The pharmaceutical composition of claim 129 , wherein:{'sub': 1', '1-6', '1-6, 'Ris hydrogen, straight or branched Calkyl, straight or branched Cheteroalkyl, or aryl; wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; and'}{'sub': '3', 'Ris hydrogen.'}131. The pharmaceutical composition of claim 129 , wherein X is oxygen.132. The pharmaceutical composition of claim 129 , wherein X is oxygen claim 129 , Ris hydrogen and Y and Z together represent —CH═CH—.134. The pharmaceutical composition of claim 129 , wherein the composition is formulated for topical administration.135. A method for treating an inflammatory and/or autoimmune disorder or a disorder resulting from increased angiogenesis and/or cell proliferation comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to a subject in need thereof a therapeutically effective amount of a compound according to .'}136. The method ...

Подробнее
01-08-2013 дата публикации

PAROXETINE DERIVATIVE

Номер: US20130197033A1
Принадлежит: Eisai R&D Management Co., Ltd.

A compound represented by Formula (1), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of paroxetine and has an improved CYP inhibitory effect: 2. The compound or pharmacologically acceptable salt thereof according to claim 1 , wherein Ris a hydrogen atom.3. The compound or pharmacologically acceptable salt thereof according to claim 1 , wherein the fluorine atom is attached at the para-position with respect to the piperidine ring.4. (3S claim 1 ,4R)-3-[(1 claim 1 ,3-Dihydro-2-benzofuran-5-yloxy)methyl]-4-(4-fluorophenyl) piperidine or a pharmacologically acceptable salt thereof.5. A pharmaceutical composition comprising the compound or pharmacologically acceptable salt thereof according to .6. The pharmaceutical composition according to claim 5 , which is a selective serotonin reuptake inhibitor.7. The pharmaceutical composition according to claim 5 , which is an antidepressant agent.8. The pharmaceutical composition according to claim 5 , which is an agent for the treatment or prevention of premature ejaculation.9. A method of selectively inhibiting serotonin reuptake comprising administering the compound or pharmacologically acceptable salt thereof according to to a patient.10. A method of treating or preventing depression comprising administering the compound or pharmacologically acceptable salt thereof according to to a patient.11. A method of treating or preventing premature ejaculation comprising administering the compound or pharmacologically acceptable salt thereof according to to a patient. This application claims the benefit of U.S. provisional application No. 61/592,896 filed on Jan. 31, 2012, the disclosure of which is herein incorporated by reference in its entiretyThe present invention relates to a compound having a phthalan ring. More specifically, it relates to a 3-[(1,3-dihydro-2-benzofuran-5-yloxy)methyl]-4-(fluorophenyl)piperidine compound.3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-phenylpiperidine compounds ...

Подробнее
01-08-2013 дата публикации

Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-Pyran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate

Номер: US20130197034A1
Принадлежит: Vitae Pharmaceuticals, Inc.

Mucic acid salts of a compound represented by the following structural formula: 145.-. (canceled)47. (canceled)48. The method of claim 46 , further comprising administering one or more additional agents selected from the group consisting of an α-blockers claim 46 , β-blocker claim 46 , a calcium channel blocker claim 46 , a diuretic claim 46 , an angiotensin converting enzyme inhibitor claim 46 , a dual angiotensin converting enzyme and neutral endopeptidase inhibitor claim 46 , an angiotensin-receptor blocker claim 46 , dual angiotensin-receptor blocker and endothelin receptor antagonist claim 46 , a aldosterone synthase inhibitor claim 46 , a aldosterone-receptor antagonist claim 46 , and an endothelin receptor antagonist.49. The method of claim 46 , wherein the salt is a hemi mucate salt.50. The method of claim 49 , wherein at least 50% by weight of the crystalline form is in a single crystalline form.51. The method of claim 49 , wherein at least 90% by weight of the crystalline form is a single crystalline form.52. The method of or claim 49 , wherein the single crystalline form is Form B.53. The method of or claim 49 , wherein the single crystalline form is Form D.54. The method of or claim 49 , wherein the single crystalline form is characterized by at least three major x-ray powder diffraction peaks at 2θ angles selected from 7.61° claim 49 , 16.38° claim 49 , 17.08° claim 49 , 19.16° and 20.12°.55. The method of or claim 49 , wherein the single crystalline form is characterized by the following major x-ray powder diffraction peaks at 2θ angles 7.61° claim 49 , 16.38° claim 49 , 17.08° claim 49 , 19.16° and 20.12°.56. The method of or claim 49 , wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of 3.79° claim 49 , 5.15° claim 49 , 6.76° claim 49 , 7.61° claim 49 , 8.83° claim 49 , 10.32° claim 49 , 11.41° claim 49 , 11.94° claim 49 , 12.47° claim 49 , 13.58° claim 49 , 15.22° claim 49 , 16.38° claim 49 , 17.08° ...

Подробнее
15-08-2013 дата публикации

CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER

Номер: US20130209505A1
Автор: Rapta Miroslav
Принадлежит:

The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases. 1. Crystalline (2S ,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1 ,2 ,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1 ,3]dioxol-4-ylmethyl ester , characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.62±0.20 , 9.50±0.20 , 12.14±0.20 , 15.18±0.20 , 15.72±0.20 , 19.90±0.20 , 20.40±0.20 , 23.42±0.20 , and 25.70±0.20.2. The crystalline compound of claim 1 , which is further characterized by having one or more additional diffraction peaks at 2θ values selected from 8.20±0.20 claim 1 , 11.14±0.20 claim 1 , 11.80±0.20 claim 1 , 14.02±0.20 claim 1 , 17.44±0.20 claim 1 , 18.42±0.20 claim 1 , 19.20±0.20 claim 1 , 21.04±0.20 claim 1 , 21.78±0.20 claim 1 , 22.24±0.20 claim 1 , 23.90±0.20 claim 1 , 24.50±0.20 claim 1 , 25.98±0.20 claim 1 , and 26.98±0.20.3. The crystalline compound of claim 1 , which is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in .4. The crystalline compound of claim 1 , which is characterized by a differential scanning calorimetry thermogram which has a melting point of about 155.3° C.5. The crystalline compound of claim 1 , which is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in .6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline compound of .7. The pharmaceutical composition of claim 6 , further comprising a therapeutic agent selected ...

Подробнее
15-08-2013 дата публикации

SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES

Номер: US20130210625A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

Compounds of the formula (I), wherein the substituents are as defined in claim , are useful as a pesticides. 3. A pesticidal composition comprising a pesticidal effective amount of at least one compound of formula I according to .4. A pesticidal composition according to claim 3 , which claim 3 , in addition to comprising the compound of formula I claim 3 , comprises formulation adjuvants.5. A pesticidal composition according to claim 3 , which claim 3 , in addition to comprising the compound of formula I claim 3 , comprises at least one additional insecticide claim 3 , acaricide claim 3 , nemacitide or molluscicide.6. A pesticidal composition according to claim 3 , which claim 3 , in addition to comprising the compound of formula I claim 3 , comprises at least one additional fungicide claim 3 , herbicide claim 3 , safener or plant growth regulator.7. A method of combating and controlling pests which comprises applying to a pest claim 3 , to a locus of a pest claim 3 , or to a plant susceptible to attack by a pest a pesticidally effective amount of a compound of formula I.8. A method of combating and controlling pests which comprises applying to a pest claim 3 , to a locus of a pest claim 3 , or to a plant susceptible to attack by a pest a pesticidal composition according to . The present invention relates to new substituted spiroheterocyclic pyrrolidine dione derivatives, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.Spiroheterocyclic pyrrolidine dione derivatives are disclosed for example in WO 09/049,851, WO 10/063,670 and WO 10/066,780.It has now surprisingly been found that certain new substituted spiroheterocyclic pyrrolidine dione derivatives have good insecticidal properties.The present invention therefore provides compounds of the formula Iwherein X, Y ...

Подробнее
15-08-2013 дата публикации

siRNA Targeting Myeloid Differentiation Primary Response Gene (88) (MYD88)

Номер: US20130210676A1
Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.

Подробнее
15-08-2013 дата публикации

ANDROGEN INDUCED OXIDATIVE STRESS INHIBITORS

Номер: US20130210772A1
Принадлежит: COLBY PHARMACEUTICAL COMPANY

Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer. 2. The compound of wherein Ris OH.3. (canceled)4. (canceled)5. The compound of wherein Ris S(═O)OH.6. The compound of wherein Ris —N═N-aryl.7. The compound of wherein aryl is naphthyl.8. (canceled)9. The compound of wherein Ris OH.10. The compound of wherein n is 1.11. (canceled)12. The compound of wherein Ris S(═O)OH.1323.-. (canceled)24. The compound of wherein Ris —N═N-aryl.25. The compound of wherein aryl is naphthyl.2633.-. (canceled)3567.-. (canceled)69. (canceled)70. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , prodrug or metabolite thereof and a pharmaceutically acceptable binder claim 1 , excipient claim 1 , or diluent thereof.71. A method of inhibiting the growth of human prostate cancer in a subject comprising administering to a subject in need thereof an inhibitor of the JunD-AR interaction.72. The method of wherein the inhibitor of the JunD-AR interaction is a compound of .73. A method of preventing interaction of androgen receptor with other transcription factors comprising contacting a compound of with an androgen receptor and/or a transcription factor wherein the interaction of androgen receptor with other transcription factors is prevented or minimized.74. The method of wherein the transcription factor is AP-1 transcription factor JunD.75. A method of reducing oxidative stress and/or blocking androgen-induced oxidative stress in cancer cells and/or tissues comprising contacting the cancer cells and/or tissues with a compound of any of wherein the oxidative stress in the cancer cell and/or tissue is reduced or the androgen-induced oxidative stress in the cancer cell and/or tissue is blocked.76. (canceled)77. The pharmaceutical composition of for the treatment of a prostate disease or disorder.78. The pharmaceutical ...

Подробнее
15-08-2013 дата публикации

PURIFICATION OF POSACONAZOLE AND OF POSACONAZOLE INTERMEDIATES

Номер: US20130211086A1
Принадлежит: SANDOZ AG

The present invention relates to a process for the preparation of a hydrogen chloride (HCl) salt of a compound of formula (I) wherein Yand Yare independently F or Cl, preferably F, said compound of formula (I) containing the cis-isomer and the trans-isomer, wherein the process comprises (1) providing the compound of formula (I) comprised in a first suitable solvent; and (2) treating the compound of formula (I) comprised in the first suitable solvent with HCl comprised in a second suitable solvent to obtain the HCl salt of the compound of formula (I). 2. The process of claim 1 , wherein the compound of formula (I) provided in (1) contains from 80 to 95% claim 1 , preferably from 85 to 95% of the cis-isomer of formula (II) and from 20 to 5% claim 1 , preferably from 15 to 5% of the trans-isomer of formula (III).4. The process of claim 3 , wherein the method according to which the compound of formula (I) is provided in (1) further comprises(vii) at least partially crystallizing the compound of formula (I) after (vi.2).5. The process of claim 1 , wherein the first suitable solvent in which the compound of formula (I) is comprised is an organic solvent claim 1 , preferably an alcohol and/or a precursor of an alcohol claim 1 , an ether claim 1 , a ketone claim 1 , an ester claim 1 , or a mixture of two or more thereof.6. The process of claim 1 , wherein the first suitable solvent in which the compound of formula (I) is comprised is selected from the group consisting of ethyl acetate claim 1 , isopropyl acetate claim 1 , diethyl ether claim 1 , tetrahydrofuran (THF) claim 1 , methyl tetrahydrofuran claim 1 , dioxane claim 1 , methanol claim 1 , n-propanol claim 1 , 1-butanol claim 1 , 2-butanol claim 1 , 2-methyl-1-butanol claim 1 , 3-methyl-1-butanol claim 1 , acetone claim 1 , 2-butanone claim 1 , and methyl isobutyl ketone (MIBK) claim 1 , and wherein the second solvent is selected from the group consisting of dioxane claim 1 , tetrahydrofuran (THF) claim 1 , diethyl ...

Подробнее
22-08-2013 дата публикации

COMPOSITIONS OF AZIMILIDE DIHYDROCHLORIDE

Номер: US20130217701A1
Принадлежит: WARNER CHILCOTT COMPANY, LLC

The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof. 1. A method for preparing an isopropanol solvate of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2 ,4-imidazolidinedione dihydrochloride in substantially pure form , wherein the method comprises:(a) heating a mixture of water and (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride to form a heated mixture;(b) combining the heated mixture with acetone;(c) isolating a hemi-hydrate of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride; and(d) combining the hemi-hydrate with isopropanol to form the isopropanol solvate of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride.2. The method of claim 1 , where method further comprises recrystallizing the isopropanol solvate in acetone in a step (e).3. The method of claim 1 , wherein the isopropanol solvate comprises between about 9% and about 11% isopropanol by weight.4. The method of claim 1 , wherein the isopropanol solvate comprises an X-ray diffraction pattern characterized substantially in accordance with the pattern of .5. The method of claim 1 , wherein the isopropanol solvate comprises has a solid-state 13C NMR spectrum characterized substantially in accordance with the solid-state 13C NMR spectrum of .6. The method of claim 1 , wherein the isopropanol solvate has an infrared spectrum characterized substantially in accordance with the infrared spectrum of .7. The method of claim 1 , wherein the isopropanol solvate has a thermogravimetric analysis curve characterized substantially in accordance ...

Подробнее
22-08-2013 дата публикации

COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6

Номер: US20130217704A1
Принадлежит:

Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes. 136-. (canceled)38. The compound of wherein D is hydrogen or heteroaralkyl.40. The compound according to claim 37 , wherein q is 0 claim 37 , and R′ is methylene.41. The compound according to wherein D is H or heteroaralkyl.42. The compound according to wherein R″ is heteroaryl claim 41 , or claim 41 , heteroaralkyl.43. The compound according to wherein R″ is alkylcarbamoyl substituted C-Calkyl.44. The compound according to wherein q is 1 claim 37 , and D is H or alkyl.45. The compound according to wherein R″ is alkyl.46. A pharmaceutical formulation comprising a pharmaceutically acceptable diluent claim 37 , adjuvant or excipient claim 37 , and a therapeutically effective amount of a compound according to . This application claims priority to provisional application Ser. No. 60/990,868 filed Nov. 28, 2007, the contents of which are herein incorporated by reference in their entirety. Compounds and methods for inhibiting cytochrome P450 2D6 enzymes are provided. Also provided are methods of enhancing the therapeutic effect of drugs that are metabolized by cytochrome P450 2D6 enzymes, methods of decreasing the toxic effects of drugs that are metabolized to toxic by-products by cytochrome P450 2D6 enzymes, methods of increasing oral bioavailability of drugs that are metabolized by cytochrome P450 2D6 enzymes, and methods of curing diseases that are caused or exacerbated by the activity of cytochrome P450 2D6 enzymes.Cytochrome P450s (P450) are a family of enzymes involved in the oxidative metabolism of both endogenous and exogenous compounds. ...

Подробнее
29-08-2013 дата публикации

PROCESS FOR PREPARING VILAZODONE HYDROCHLORIDE

Номер: US20130225818A1
Принадлежит: ERREGIERRE S.P.A.

The present invention relates, in a first aspect, to a process preparing vilazodone hydrochloride that comprises the reaction of 3-(4-chloro-1-hydroxy-butyl)-1H-indol-5-carbonitrile with 5-piperazin-1-yl-benzofuran-2-carboxylate methyl hydrochloride with the formation of a 1,4-piperazine, with subsequent dehydration, hydrogenation and treatment with ammonia, to obtain vilazodone in free base form that is then converted into the hydrochloride thereof. 2. A process according to claim 1 , wherein step A) is carried out in the presence of a weak base and an organic solvent.3. A process according to claim 2 , wherein the weak base is sodium bicarbonate and the organic solvent is a dipolar aprotic solvent.4. The process according to wherein the organic solvent is N claim 2 ,N-dimethylacetamide.5. A process according to wherein the acidification agent in step B) is ammonium chloride.6. A process according to claim 1 , wherein step B) comprises heating the compound of formula (III) in a mixture with N claim 1 ,N-dimethylacetamide and ammonium chloride.7. A process according to wherein the hydrogenation step C) with His carried out in the presence of a Pd/C or Raney nickel catalyst and an alcoholic solvent.8. A process according to wherein in step D) the compound of formula (V) is dissolved in an alcoholic solvent claim 1 , wherein gaseous ammonia is bubbled.9. The process according to wherein the alcoholic solvent is methanol.11. A process according to claim 10 , wherein step i) comprises preparing a solution of 4-chlorobutyryl in a chlorinated organic solvent claim 10 , preferably methylene chloride claim 10 , in the presence of an activating agent claim 10 , preferably aluminum chloride claim 10 , and adding the solution containing 1H-indol-5-carbonitrile in a chlorinated organic solvent claim 10 , preferably methylene chloride claim 10 , to this solution.12. A process according to wherein step ii) comprises dissolving the sodium borohydride reducing agent in an alkaline ...

Подробнее
05-09-2013 дата публикации

BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

Номер: US20130231338A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. 2. A compound according to wherein:{'sup': '1', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '2', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '3', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '4', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '5', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '6', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '7', 'sub': '1-6', 'Ris halogen or substituted or unsubstituted Calkyl;'}{'sup': '8', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '9', 'sub': '2', 'Ris S, S(O) or S(O)'}a is 1;{'sup': '11', 'sub': 6-10', '3-8, 'Ris substituted or unsubstituted Caryl, substituted or unsubstituted heterocycle or substituted or unsubstituted Ccycloalkyl;'}{'sup': '17', 'X is CR;'}{'sup': '17', 'Ris hydrogen; and'}{'sup': '18', 'sub': '1-6', 'Ris hydrogen or substituted or unsubstituted Calkyl.'}3. A compound according to selected from:N-[5-chloro-2-(phenylsulfanyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-chloro-2-(phenylsulfonyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-chloro-2-(phenylsulfinyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-methyl-2-(phenylsulfanyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-methyl-2-(phenylsulfinyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-methyl-2-(phenylsulfonyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-fluoro-2-(phenylsulfanyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-fluoro-2-(phenylsulfinyl)phenyl]-1-benzofuran-2-sulfonamide;N-[5-fluoro-2-(phenylsulfonyl)phenyl]-1-benzofuran-2-sulfonamide;2-({2-[(1-benzofuran-2-ylsulfonyl)amino]- ...

Подробнее
05-09-2013 дата публикации

BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

Номер: US20130231339A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. 2. A compound according to wherein:{'sup': '1', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '2', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '3', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '4', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': '5', 'sub': '1-6', 'Ris hydrogen, halogen or substituted or unsubstituted Calkyl;'}{'sup': 6', '12', '13', '14', '15, 'sub': '1-6', 'Ris hydrogen, halogen, CN, substituted or unsubstituted Calkyl, OR, NRR, or COR;'}{'sup': 7', '12', '13', '14', '15, 'sub': '1-6', 'Ris hydrogen, halogen, CN, substituted or unsubstituted Calkyl, OR, NRR, or COR;'}{'sup': 8', '12', '13', '14', '15, 'sub': '1-6', 'Ris hydrogen, halogen, CN, substituted or unsubstituted Calkyl, OR, NRR, or COR;'}{'sup': '9', 'sub': '2', 'Ris S, S(O), S(O);'}a is 0 or 1;{'sup': 11', '12', '13', '14', '15, 'sub': 1-6', '3', '6-10', '3-8', '2-6', '2-6, 'Ris hydrogen, CN, substituted or unsubstituted Calkyl, CF, OR, NRR, substituted or unsubstituted Caryl, substituted or unsubstituted heterocycle, substituted or unsubstituted Ccycloalkyl, substituted or unsubstituted Calkyne, substituted or unsubstituted Calkene or COR;'}{'sup': '12', 'sub': '1-6', 'Ris hydrogen or substituted or unsubstituted Calkyl;'}{'sup': 13', '14, 'sub': '1-6', 'Ris hydrogen or substituted or unsubstituted Calkyl or can from an optionally substituted heterocycle with R;'}{'sup': 14', '13, 'sub': 1-6', '6-10, 'Ris hydrogen, substituted or unsubstituted Calkyl, substituted or unsubstituted heterocycle or substituted or unsubstituted Caryl or can from an optionally substituted heterocycle with R;'}{'sup': '15', ' ...

Подробнее
12-09-2013 дата публикации

N-ARYL PYRAZOLE(THIO)CARBOXAMIDES

Номер: US20130237500A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to novel (thio)carboxamides, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 2. A compound according to claim 1 , wherein Xand Xindependently from each other represents fluorine or chlorine.3. A compound according to claim 1 , wherein Rrepresents a substituted or non-substituted C-C-alkyl claim 1 , a C-C-halogenoalkyl having 1 to 5 halogen atoms or a non-substituted C-C-cycloalkyl.4. A compound according to claim 3 , wherein Rrepresents methyl or cyclopropyl.6. A compound according to claim 5 , wherein M represents M-1 or M-3.7. A compound according to wherein n is 0 or 1 and Rrepresents fluorine.8. A compound according to wherein Q represents a direct bond or O (oxygen).9. A compound according to claim 1 , wherein Rrepresents hydrogen claim 1 , C-C-alkyl claim 1 , C-C-alkoxy-C-C-alkyl claim 1 , C-C-alkylsulfanyl-C-C-alkyl or C-C-cycloalkyl.10. A compound according to claim 1 , wherein Wrepresents fluorine claim 1 , chlorine claim 1 , bromine claim 1 , methyl claim 1 , ethyl claim 1 , n- or i-propyl claim 1 , n- claim 1 , i- claim 1 , s- or t-butyl claim 1 , methoxy claim 1 , ethoxy claim 1 , n- or i-propoxy claim 1 , trifluoromethyl claim 1 , trifluoroethyl claim 1 , difluoro-methoxy claim 1 , trifluoromethoxy claim 1 , difluorochloromethoxy claim 1 , trifluoroethoxy claim 1 , in each case doubly attached difluoromethylenedioxy or tetrafluoroethylenedioxy claim 1 , or the groupings —CHSi(CH) claim 1 , —Si(CH)or —C(Q)=N-Q claim 1 , in which{'sup': '2', 'Qrepresents hydrogen, methyl, ethyl or trifluoromethyl and'}{'sup': '3', 'Qrepresents hydroxyl, methoxy, ethoxy, propoxy or isopropoxy.'}11. A compound according to claim 1 , wherein Zrepresents 2-pyridinyl claim 1 , 3-pyridinyl or 4-pyridinyl claim 1 , each of which is optionally mono- to trisubstituted by ...

Подробнее
12-09-2013 дата публикации

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Номер: US20130237568A1
Принадлежит:

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 165-. (canceled)6769-. (canceled)70. The method of claim 66 , wherein the patient has two copies of the defective gene.72. The method of claim 71 , wherein the patient has two copies of the defective gene.73. The method of or claim 71 , wherein the composition further comprises a mucolytic agent claim 71 , a bronchodilator claim 71 , an antibiotic claim 71 , an anti-infective agent claim 71 , an anti-inflammatory agent claim 71 , a CFTR modulator claim 71 , or a nutritional agent.74. The method of or claim 71 , wherein the composition further comprises a CFTR modulator.75. The method of or further comprising the additional step of administering to the patient a mucolytic agent claim 71 , a bronchodilator claim 71 , an antibiotic claim 71 , an anti-infective agent claim 71 , an anti-inflammatory agent claim 71 , a CFTR modulator claim 71 , or a nutritional agent.76. The method of or claim 71 , wherein the method comprises the additional step of administering to the patient a CFTR modulator.78. The method of claim 77 , wherein the compound is administered concurrently with the CFTR modulator.79. The method of claim 77 , wherein the compound is administered prior to the CFTR modulator. The present application is a continuing application of and claims the benefit of priority under 35 U.S.C. §120 of co-pending International Application Serial No. PCT/US06/043289, filed Nov. 8, 2006, which claims the benefit, under 35 U.S.C. §119, of U.S. provisional patent application Ser. Nos. 60/734,506, filed on Nov. 8, 2005; 60/754,086, filed on Dec. 27, 2005; and 60/802,458, filed on May 22, 2006, the ...

Подробнее
19-09-2013 дата публикации

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Номер: US20130245010A1
Принадлежит:

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 261-. (canceled)62. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) a compound according to ; and'}(ii) a pharmaceutically acceptable carrier.63. The composition according to claim 62 , optionally further comprising a mucolytic agent claim 62 , a bronchodialator claim 62 , an antibiotic claim 62 , an anti-infective agent claim 62 , an anti-inflammatory agent claim 62 , a CFTR modulator claim 62 , or a nutritional agent.6469-. (canceled)70. The composition of claim 62 , further comprising a CFTR modulator.72. The compound of claim 1 , wherein T is —CF—.73. The compound of claim 1 , wherein R′ is H claim 1 , methyl claim 1 , ethyl claim 1 , i-propyl claim 1 , t-butyl claim 1 , F claim 1 , Cl claim 1 , CF claim 1 , OCF claim 1 , CHF claim 1 , —OCH claim 1 , —OCHCH claim 1 , —O-(i-propyl) claim 1 , or —O-(t-butyl).74. The compound of claim 1 , wherein R′ is methyl.75. The compound of claim 1 , wherein R″ is H claim 1 , methyl claim 1 , ethyl claim 1 , i-propyl claim 1 , t-butyl claim 1 , F claim 1 , Cl claim 1 , CF claim 1 , OCF claim 1 , CHF claim 1 , —OCH claim 1 , —OCHCH claim 1 , —O-(i-propyl) claim 1 , or —O-(t-butyl).76. The compound of claim 1 , wherein R″ is H.77. The compound of claim 1 , wherein for R claim 1 , Zis an optionally substituted branched or straight Caliphatic chain wherein one carbon unit of Zis replaced by —CO— claim 1 , —SO— claim 1 , —SO— claim 1 , —OCO— claim 1 , —OCO— claim 1 , —CONR— claim 1 , —NRCO— claim 1 , NRCO— claim 1 , —O— claim 1 , —NRSO— claim 1 , or —SONR—.78. The compound of claim 1 , wherein in R claim ...

Подробнее
19-09-2013 дата публикации

Modulators of ATP-Binding Cassette Transporters

Номер: US20130245011A1
Принадлежит:

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 2. The compound according to claim 1 , wherein one Rthat is attached to 5- or 6-position of the pyridyl ring is aryl or heteroaryl claim 1 , each optionally substituted with 1 claim 1 , 2 claim 1 , or 3 of R; wherein Ris —ZR; wherein each Zis independently a bond or an optionally substituted branched or straight Caliphatic chain wherein up to two carbon units of Zare optionally and independently replaced by —CO— claim 1 , —CS— claim 1 , —CONR— claim 1 , —CONRNR— claim 1 , —CO— claim 1 , —OCO— claim 1 , —NRCO— claim 1 , —O— claim 1 , —NRCONR— claim 1 , —OCONR— claim 1 , —NRNR— claim 1 , —NRCO— claim 1 , —S— claim 1 , —SO— claim 1 , —SO— claim 1 , —NR— claim 1 , —SONR— claim 1 , —NRSO— claim 1 , or —NRSONR—; each Ris independently R claim 1 , halo claim 1 , —OH claim 1 , —NH claim 1 , —NO claim 1 , —CN claim 1 , —CF claim 1 , or —OCF; and each Ris independently hydrogen claim 1 , an optionally substituted Caliphatic group claim 1 , an optionally substituted cycloaliphatic claim 1 , an optionally substituted heterocycloaliphatic claim 1 , an optionally substituted aryl claim 1 , or an optionally substituted heteroaryl.3. The compound according to claim 2 , wherein the one Rattached to the 5- or 6-position of the pyridyl ring is phenyl optionally substituted with 1 claim 2 , 2 claim 2 , or 3 of R.4. The compound according to claim 2 , wherein the one Rattached to the 5- or 6-position of the pyridyl ring is heteroaryl optionally substituted with 1 claim 2 , 2 claim 2 , or 3 of R.5. The compound according to claim 2 , wherein one Rattached to the 5- or 6-position of the pyridyl ring is a 5 ...

Подробнее
26-09-2013 дата публикации

Modulators of Aldhehyde Dehydrogenase Activity and Methods of Use Thereof

Номер: US20130253010A1

The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. 124.-. (canceled)34. The method of claim 25 , wherein the halo is bromo claim 25 , fluoro claim 25 , chloro or iodo.35. The method of claim 25 , wherein the aldehyde is produced by in vivo metabolism of a compound that is ingested.36. The method of claim 35 , wherein the compound is administered to an individual following excessive alcohol consumption.37. The method of claim 36 , wherein the compound is administered to reduce one or more symptoms of excess alcohol consumption claim 36 , wherein the symptoms are selected from a group consisting of headache claim 36 , dehydration claim 36 , fatigue claim 36 , nausea claim 36 , vomiting claim 36 , diarrhea claim 36 , weakness claim 36 , anxiety claim 36 , irritability claim 36 , photophobia claim 36 , and phonophobia.38. The method of claim 25 , wherein the acute or chronic free-radical associated disease is selected from the group consisting of seizures claim 25 , skin damage from UV exposure claim 25 , photodamage of skin claim 25 , acute thermal skin burn injury claim 25 , tissue hyperoxia claim 25 , Parkinson's disease claim 25 , and Alzheimer's disease.39. The method of claim 25 , wherein the pharmaceutical composition is administered by a route selected from intramuscular claim 25 , intravenous claim 25 , subcutaneous claim 25 , and oral.42. The method of claim 40 , wherein the aldehyde is produced by in vivo metabolism of a compound that is ingested.43. The method of claim 42 , wherein the compound is administered to an individual following excessive alcohol consumption.44. The method of claim 40 , wherein the acute or chronic free-radical associated disease is selected from the group consisting of seizures claim 40 , ...

Подробнее
17-10-2013 дата публикации

PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES

Номер: US20130274287A1
Принадлежит: Hoffmann-La Roche Inc.

The invention provides novel compounds having the general formula (I) 3. A compound according to claim 1 , wherein R claim 1 , R claim 1 , Rand Rare independently selected from H claim 1 , halogen claim 1 , cyano claim 1 , alkyl and haloalkyl.4. A compound according to claim 1 , wherein Ris H or halogen.5. A compound according to claim 1 , wherein Ris H claim 1 , alkyl or halogen.6. A compound according to claim 1 , wherein Ris H or halogen.7. A compound according to claim 1 , wherein Ris halogen claim 1 , cyano or haloalkyl.8. A compound according to claim 1 , wherein Ris cyano or haloalkyl.9. A compound according to claim 1 , wherein Ris haloalkyl.10. A compound according to claim 1 , wherein Ris H or halogen.11. A compound according to claim 1 , wherein Ris H.12. A compound according to claim 1 , wherein Ris H.13. A compound according to claim 1 , wherein Ris H or aryl substituted with R claim 1 , Rand R.14. A compound according to claim 1 , wherein Ris H.15. A compound according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rare independently selected from H and alkyl.16. A compound according to claim 1 , wherein Ris H or alkyl.17. A compound according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare H.18. A compound according to claim 1 , wherein A is —(CRR)—NRR.19. A compound according to claim 1 , wherein A is —(CRR) claim 1 , —OR.20. A compound according to claim 1 , wherein Ris H.21. A compound according to claim 1 , wherein Ris H claim 1 , alky claim 1 , —S(O)R claim 1 , —S(O)NRR claim 1 , —C(O)R claim 1 , —C(O)ORor —C(O)NRR.22. A compound according to claim 1 , wherein in case A is{'sup': 13', '14', '15', '16', '16', '17', '17', '18', '17', '17', '17', '18, 'sub': p', '2', '2, '—(CRR)—NRR, then Ris H, —S(O)R, —S(O)NRR, —C(O)R, —C(O)ORor —C(O)NRR.'}23. A compound according to claim 1 , wherein in case A is{'sup': 13', '14', '16', '16', '17', '18, 'sub': 'p', '—(CRR)—OR, then Ris H, alkyl or —C(O)NRR.'}24. A ...

Подробнее
17-10-2013 дата публикации

BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

Номер: US20130274288A1
Принадлежит: THERAVANCE, INC.

The invention provides compounds of formula I: 2. The compound of claim 1 , wherein a claim 1 , b and c each represent 0.3. The compound of claim 1 , wherein W represents O.4. The compound of claim 1 , wherein m is 0.5. The compound of claim 1 , wherein n is 0.6. The compound of claim 1 , wherein q is 0.7. The compound of claim 1 , wherein r is 1.89-. (canceled)10. The compound of claim 1 , wherein m claim 1 , n and q are 0 claim 1 , and r is 1.11. The compound of claim 1 , wherein Ris selected from hydrogen and (1-4C)alkyl.12. The compound of claim 1 , wherein Ris hydrogen.13. The compound of claim 1 , wherein Ris hydrogen.14. The compound of claim 1 , wherein Xis (1-3C)alkylene.15. The compound of claim 1 , wherein s is 0 or 1.16. The compound of claim 15 , wherein s is 1 claim 15 , and Ris —ORwhere Ris hydrogen.17. The compound of claim 1 , wherein Ris selected from hydrogen and (1-4C)alkyl.1819-. (canceled)20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of .2122-. (canceled)24. The process of claim 23 , which further comprises forming a pharmaceutically acceptable salt of the compound of formula Ia.2532-. (canceled) This application claims the benefit of U.S. Provisional Application No. 60/660,435, filed on Mar. 10, 2005; the entire disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity. The invention also relates to pharmaceutical compositions comprising such biphenyl compounds, processes and intermediates for preparing such biphenyl compounds and methods of using such biphenyl compounds to treat pulmonary disorders.2. State of the ArtPulmonary or respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma, afflict many millions of people worldwide and such disorders are a leading cause of morbidity ...

Подробнее
17-10-2013 дата публикации

PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS

Номер: US20130274477A1
Автор: Siesel David Andrew
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1). 135-. (canceled)3740-. (canceled)41. The process of claim 36 , wherein the reaction between compound 6a and compound 7a is carried out in the presence of a catalytic amine.42. The process of claim 36 , wherein the reaction between compound 6a and compound 7a is carried out in the presence of a catalytic amount of dimethylaminopyridine.43. The process of claim 36 , wherein when Ron the phenyl ring in formula 1 is an ester claim 36 , the process further comprises de-esterifying the compound of formula 1 in a biphasic mixture comprising water claim 36 , an organic solvent claim 36 , and an acid to give an acid salt.44. The process of claim 43 , wherein the organic solvent is acetonitrile.45. The process of claim 43 , the acid is an inorganic acid.46. The process of claim 43 , wherein the acid is hydrochloric acid.47. The process of claim 43 , wherein the de-esterification reaction is run at between 20° C. and 60° C.48. The process of claim 43 , wherein the acid salt is converted to the free form claim 43 , Form I claim 43 , by slurrying or dissolving the acid salt in a solvent for an effective amount of time.49. The process of claim 48 , wherein the solvent is selected from water or a 50% methanol/water mixture.50. The process of claim 48 , wherein the solvent is water.51. The process of claim 48 , wherein the effective amount of time is between 2 and 24 hours.52. The process of claim 48 , further comprising the step of filtering the slurry of the compound of formula 1 in Form I claim 48 , or concentrating the solution of the compound of formula 1 in Form I to effect recrystallization and filtering the recrystallized compound of formula 1 in Form I.53106-. (canceled)107. The process of claim 36 , wherein in step ic) claim 36 , Ris methyl. This application is a ...

Подробнее
24-10-2013 дата публикации

Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA)

Номер: US20130281490A1
Принадлежит:

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder. 216-. (canceled)18. (canceled)19. A compound of claim 17 , wherein Y is a bond claim 17 , an optionally substituted alkyl claim 17 , an optionally substituted alkenyl claim 17 , an optionally substituted cycloalkyl claim 17 , an optionally substituted heterocyclyl claim 17 , or a group —(CRR)-Q—(CRR)—; W is H claim 17 , an optionally substituted aryl claim 17 , an optionally substituted heteroaryl claim 17 , an optionally substituted heterocyclyl claim 17 , an optionally substituted cycloalkyl claim 17 , a group —C(O)—R claim 17 , or a group —(CRR)—CRRR.20. A compound of claim 19 , wherein Y is pentyl.21. A compound of claim 17 , wherein Ris H and Ris lower alkyl.22. A compound of claim 17 , wherein Ris methyl.23. A compound of claim 17 , wherein Ris ethyl.24. A compound of wherein Ris iso-propyl.25. A compound of wherein Ris t-butyl.26. A compound of wherein Q is O.27. A compound of in which n is 2 claim 17 , 3 claim 17 , or 4.28. A compound of in which m is 0 claim 17 , 1 claim 17 , 2 claim 17 , or 3.29. A compound of in which p is 0 claim 17 , 1 claim 17 , 2 claim 17 , or 3.30. A compound of claim 17 , wherein W is cyclohexyl claim 17 , phenyl claim 17 , or biphenyl.31. A compound of claim 30 , wherein W is unsubstituted cyclohexyl claim 30 , unsubstituted phenyl claim 30 , or unsubstituted biphenyl.32. A compound of claim 17 , in which W is phenyl optionally substituted with one to five substituents selected from the group consisting of methyl ...

Подробнее
07-11-2013 дата публикации

MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS

Номер: US20130296364A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 145-. (canceled)4749-. (canceled)50. The method of claim 46 , wherein the patient has two copies of the defective gene.52. The method of claim 51 , wherein the patient has two copies of the defective gene.53. The method of or claim 51 , wherein the composition further comprises a mucolytic agent claim 51 , a bronchodialator claim 51 , an antibiotic claim 51 , an anti-infective agent claim 51 , an anti-inflammatory agent claim 51 , a CFTR modulator claim 51 , or a nutritional agent.54. The method of or claim 51 , wherein the composition further comprises a CFTR modulator. This application claims the benefit under 35 U.S.C. §119 to U.S. provisional patent application Ser. No. 60/988,559, filed Nov. 16, 2007, the entire contents of which are incorporated herein by reference.The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions. ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were discovered as multi-drug resistance proteins (like the MDR1-P glycoprotein, or the multi-drug resistance protein, MRP1), ...

Подробнее
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296371A1
Принадлежит: DOW AGROSCIENCES LLC

The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein:{'sub': 1', '3', '2', '3, 'Ris H, —C(O)R, or —CHOC(O)R;'}{'sub': 2', '5, 'Ris alkyl, alkenyl, or aryl, each substituted with 0, 1 or multiple R;'}{'sub': 3', '5, 'Ris alkyl or alkoxy, substituted with 0, 1, or multiple R;'}{'sub': 5', '6, 'Ris alkyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl, each substituted with 0, 1 or multiple R; and'}{'sub': '6', 'Ris alkyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, cyano, aryl or heterocyclyl.'}3. A compound according to claim 3 , wherein:{'sub': 1', '3', '2', '3, 'Ris H, —C(O)R, or —CHOC(O)R;'}{'sub': 2', '5, 'Ris alkyl, alkenyl, or aryl, each substituted with 0, 1 or multiple R;'}{'sub': 3', '5, 'Ris alkyl or alkoxy, substituted with 0, 1, or multiple R; and'}{'sub': '5', 'Ris alkyl, halo, haloalkyl, or aryl.'}4. A compound according to claim 3 , wherein:{'sub': 1', '3', '2', '3, 'Ris H, —C(O)R, or —CHOC(O)R;'}{'sub': 2', '5, 'Ris alkyl, alkenyl, or aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris alkyl; and'}{'sub': '5', 'Ris alkyl, halo, haloalkyl, or aryl.'}7Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisMycosphaerella fujiensis. The compositions according to claim 6 , wherein the effective amount of the compound is effective against at least one plant pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 6 , Wheat Brown Rust () claim 6 , Stripe Rust () claim 6 , and Black Sigatoka ().8Septoria triticiPuccinia triticina. The composition according to claim 7 , wherein the plant pathogen is at least one organism selected from the group consisting of () and (). This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/643,623 filed May 7, 2012, which is expressly incorporated by reference herein.Fungicides are ...

Подробнее
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296373A1
Принадлежит: DOW AGROSCIENCES LLC

The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are independently chosen from H or C(O)R.3. The compound according to claim 2 , wherein Ris independently chosen from H claim 2 , alkyl claim 2 , alkenyl claim 2 , aryl claim 2 , heterocyclyl claim 2 , silyl claim 2 , —C(O)R claim 2 , each substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 3 , wherein Ris independently phenyl or cyclohexyl.5. The compound according to claim 4 , wherein Ris alkyl or aryl substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. The compound according to claim 5 , wherein Ris alkoxy or benzyloxy substituted with 0 claim 5 , 1 claim 5 , or multiple R.7. The compound according to claim 6 , wherein Ris hydrogen or alkyl.8. The compound according to claim 1 , wherein X is H and Y is Q.10. The compound according to claim 9 , wherein Ris independently chosen from alkyl claim 9 , aryl claim 9 , or —C(O)R claim 9 , each substituted with 0 claim 9 , 1 or multiple R.11. The compound according to claim 10 , wherein Ris phenyl.12. The compound according to claim 11 , wherein Ris alkyl substituted with 0 claim 11 , 1 claim 11 , or multiple R.13. The compound according to claim 12 , wherein Ris alkyl claim 12 , aryl claim 12 , alkoxy claim 12 , or halo.14. A composition for the control of a fungal pathogen including at least one of the compounds according to and a phytologically acceptable carrier material.16Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The composition according to claim claim 1 , 14 wherein the plant pathogen is at least one ...

Подробнее
07-11-2013 дата публикации

USE OF PRO-FUNGICIDES OF UK-2A FOR CONTROL OF BLACK SIGATOKA

Номер: US20130296374A1
Принадлежит: DOW AGROSCIENCES LLC

The present disclosure is related to the field of agrochemicals, including profungicides of UK-2A and their use to control Black Sigatoka. 3. The method of claim 1 , wherein the composition further includes at least one additional agriculturally active ingredient selected from the group consisting of: an insecticide claim 1 , an herbicide claim 1 , and a fungicide.4. The method of claim 1 , wherein the plant pathogen is Black Sigatoka.5. The method of wherein the composition further includes at least one additional agriculturally active ingredient selected from the group consisting of: an insecticide claim 2 , an herbicide claim 2 , and a fungicide.6. The method of wherein the plant pathogen is Black Sigatoka.7Mycosphaerella fijiensis.. The method according to claim 1 , wherein the pathogen is This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/643,630 filed May 7, 2012, which is expressly incorporated herein by reference.This present disclosure is related to the field of profungicides of UK-2A to control Black Sigatoka.Fungicides are compounds, of natural or synthetic origin, which act to protect and cure plants against damage caused by agriculturally-relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less.The present disclosure relates to profungicides of UK-2A and their use as fungicides. Profungicides of UK-2A may offer protection against ascomycetes, basidiomycetes, deuteromycetes and oomycetes.One embodiment of the present disclosure includes a method of controlling a pathogen-induced disease in a plant that is at risk of being diseased from the pathogen comprising contacting the plant or an area adjacent to the plant with a composition including profungicides of UK-2A.Another embodiment of the present disclosure is a use of profungicides of UK-2A for protection of a plant against ...

Подробнее
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296375A1
Принадлежит: DOW AGROSCIENCES LLC

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein:{'sub': '6', 'wherein, R is H, C(O)R;'}{'sub': 1', '6, 'Ris H, C(O)R;'}{'sub': 2', '5, 'Ris independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris independently or separately H, methyl;'}{'sub': '5', 'Ris alkyl, alkoxy, halo, haloalkyl, or aryl; and'}{'sub': '6', 'Ris alkoxy, benzyloxy.'}5Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 4 , wherein the plant pathogen is least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 4 , Wheat Brown Rust () claim 4 , Stripe Rust () claim 4 , Scab of Apple () claim 4 , Blister Smut of Maize () claim 4 , Powdery Mildew of Grapevine () claim 4 , Barley scald () claim 4 , Blast of Rice () claim 4 , Downy Mildew of Cucurbits () claim 4 , Rust of Soybean () claim 4 , Glume Blotch of Wheat () claim 4 , Powdery Mildew of Wheat (f. sp. ) claim 4 , Powdery Mildew of Barley (f. sp. ) claim 4 , Powdery Mildew of Cucurbits () claim 4 , Anthracnose of Cucurbits () claim 4 , Leaf Spot of Beet () claim 4 , Early Blight of Tomato () claim 4 , and Net Blotch of Barley ().6Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to claim 5 , wherein the fungal pathogen is at least one of Leaf Blotch of Wheat () claim 5 , Wheat Brown Rust () claim 5 , and Rust of Soybean ().8. The method according to claim 7 , wherein the compound is applied in a mixture with at least one additional compound selected from the group ...

Подробнее
07-11-2013 дата публикации

METHYLTETRAZOLE SULFIDES AND SULFONES

Номер: US20130296563A1
Автор: De Lange Ben

The present invention relates to a process for the preparation of a 1-methyl-1H-tetrazole-5-thio derivative comprising reaction of a halomethyl substrate with 1-methyl-H-tetrazole-5-thiol to obtain a thio-ether compound, and oxidizing the thio-ether compound to the corresponding sulfone. In case of a chiral halomethyl substrate, the resulting chiral diol sulfone derivative is suitable as a building block for statin type compounds.

Подробнее
14-11-2013 дата публикации

PROCESS FOR THE PREPARATION OF DIOL SULFONES

Номер: US20130303779A1

The present invention relates to a process for the preparation of a diol sulfone derivative comprising reaction of a halomethyl substrate with a thio-aryl compound to obtain a thio-ether compound, and oxidizing the thio-ether compound to the corresponding sulfone. In case of a chiral halomethyl substrate, the resulting chiral diol sulfone derivative is suitable as a building block for statin type compounds. 2. Process according to wherein Ris bromine or chlorine claim 1 , Ris ethyl or methyl and Ris ethyl or methyl or Rand Rform a cyclopentyl ring or a cyclohexyl ring together with the carbon atom to which they are bound claim 1 , Ris tert-butyl claim 1 , ethyl claim 1 , methyl claim 1 , or iso-propyl claim 1 , Ris methoxyethoxymethyl claim 1 , tetrahydrofuranyl or tetrahydropyranyl and Ris 1-methyl-1H-tetrazol-5-yl claim 1 , 1-phenyl-1H-tetrazol-5-yl claim 1 , 1-tert-butyl-1-H-tetrazol-5-yl claim 1 , benzothiazol-2-yl or 3 claim 1 ,5-bis(trifluoromethyl)phenyl-1-yl.3. Process according to wherein said compound of general formula (3a) or (3b) is isolated and/or wherein said compound of general formula (4a) or (4b) is isolated.4. Process according to wherein said oxidation is carried out in the presence of hydrogen peroxide or a peracid or bleach or tert-BuOCl or a perborate or an N-oxide or a permanganate or a chromate or a chlorate or a bromate or a perchlorate or a periodate or tert-butyl hydroperoxide or oxone or a peroxodisulfate or oxygen or mixtures thereof.6. Process according to carried out in the presence of a sodium-comprising base.7. Process according to wherein said sodium-comprising base is sodium hexamethyldisilazane.8. Process according to followed by deprotection and isolation.10. Compound according to wherein Ris chosen from the group consisting of pyridine-2-yl claim 9 , pyrimidin-2-yl claim 9 , benzothiazol-2-yl claim 9 , 1-methyl-1H-tetrazol-5-yl claim 9 , 1-phenyl-1H-tetrazol-5-yl claim 9 , 1-tert-butyl-1-H-tetrazol-5-yl claim 9 , 1- ...

Подробнее
28-11-2013 дата публикации

NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

Номер: US20130317220A1
Принадлежит: ACTAVIS GROUP PTC EHF

Provided herein is a novel process for the preparation of triazolo[4,5-d]pyrimidine derivatives. Provided particularly herein is a novel, commercially viable and industrially advantageous process for the preparation of highly pure ticagrelor or a pharmaceutically acceptable salt thereof. Provided further herein is a novel process for the preparation of substituted cyclopentanamine derivatives, which are useful intermediates in the preparation of triazolo[4,5-d]pyrimidine compounds. Provided particularly herein is a novel, commercially viable and industrially advantageous process for the preparation of a ticagrelor intermediate, 2-[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-yl]oxy]-1-ethanol. 3. (canceled)4. (canceled)714-. (canceled)15. The process of claim 1 , wherein the protecting groups Pand Pare defined according to one of (a) claim 1 , (b) claim 1 , or (c):{'sub': 1', '2', '1-6', '1-6', '3', '1-6, '(a) the protecting groups Pand Pin the compounds of formulae VII, VIII, IX and X are Calkyl, benzyl, (Calkyl)Si, and C(O)Calkyl,'}(b) the protecting groups in the compounds of formulae VII, VIII, IX and X are methyl, benzyl, t-butyldimethylsilyl and acetyl; or{'sub': 1', '2, '(c) the protecting groups Pand Ptogether with the atoms to which they are attached form an isopropylidene ring'}16. (canceled)17. (canceled)18. The process of claim 1 , wherein the solvents are defined according to (a) or (b):(a) the first solvent used in step-(a) is selected from the group consisting of a ketone, an aliphatic or alicyclic hydrocarbon, a chlorinated aliphatic or aromatic hydrocarbon, an aromatic mono or dinitro hydrocarbon, an aliphatic or cyclic ether, a polar aprotic solvent, and mixtures thereof; wherein the second solvent used in step-(b) is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, acetonitrile, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, diethyl ...

Подробнее
05-12-2013 дата публикации

Methods for treating neurological disease

Номер: US20130324583A1
Принадлежит: Neurim Pharmaceuticals 1991 Ltd

Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar—B—Ar′  (I) wherein AR represents an indole nucleus ring system: Ar′ represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R 1 , R 2 , R 3 , R 4 , R 1 ′ and R 2 ′ are as defined herein.

Подробнее
05-12-2013 дата публикации

CATHEPSIN C INHIBITORS

Номер: US20130324584A1
Принадлежит:

Disclosed are -amino--butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease. 112-. (canceled)15. A pharmaceutical composition which comprises the compound or salt according to claim 13 , and a pharmaceutically acceptable excipient.16. A pharmaceutical composition which comprises the compound according to claim 14 , and a pharmaceutically acceptable excipient.17. A process for preparing the composition as defined in claim 15 , the process comprising mixing the compound or salt with the pharmaceutically acceptable excipient.18. A process for preparing the composition as defined in claim 16 , the process comprising mixing the compound with the pharmaceutically acceptable excipient. This application claims the benefit of U.S. Provisional Application No. 61/441,840 filed on 11 Feb. 2011, which is incorporated herein in its entirety.The present invention relates to certain 4-amino-2-butenamides that are cathepsin C inhibitors, pharmaceutical compositions containing these compounds, and their use in the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.Cathepsins are a family of enzymes included in the papain superfamily of cysteine proteases. Cathepsins B, C, F, H, K, L, S, V, and X have been described in the scientific literature. Cathepsin C is also known in the literature as Dipeptidyl Peptidase I or “DPPI.”A number of recently published studies have begun to describe the role cathepsin C plays in certain inflammatory processes. See e.g. Adkison et al., The Journal of Clinical Investigation 109:363-371 (2002); Tran et al., Archives of Biochemistry and Biophysics 403:160-170 (2002); Thiele et al., The Journal of Immunology 158: 5200-5210 (1997); Bidere et al., The Journal of Biological Chemistry 277: 32339-32347 (2002); Mabee et al., The Journal ...

Подробнее
05-12-2013 дата публикации

PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE COMPOUNDS

Номер: US20130324743A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis. 2. The method of claim 1 , wherein ring A is a fused heterocycloalkyl or heteroaryl.4. The method of claim 1 , wherein X is CN or COEt.5. (canceled)6. The method of claim 1 , wherein Ris a Caliphatic; Hal is Br; and the first organic solvent is an aprotic solvent.7. (canceled)8. (canceled)9. The method of claim 1 , wherein the first organic solvent is toluene.10. The method of claim 1 , wherein step a) is carried out at about 50° C. to 90° C. in the presence of a palladium catalyst which is selected from palladium(II)acetate claim 1 , Pd(dppf)Cl claim 1 , Pd(dba) claim 1 , tetrakis(triphenylphosphine)palladium(0) or tris(dibenzylideneacetone)dipalladium(0).11. (canceled)12. The method of claim 1 , wherein step a) is carried out in the presence of Pd(dba).13. (canceled)14. The method of claim 1 , wherein step a) is carried out at about 70° C.15. (canceled)16. The method of claim 1 , wherein the second organic solvent is dimethylsulfoxide.17. The method of claim 1 , wherein step b) is carried out in the presence of an inorganic acid at about 55° C. to 95° C.18. (canceled)19. The method of claim 1 , wherein step b) is carried out at about 75° C.21. (canceled)22. The method of claim 20 , wherein in step a) claim 20 , the first organic solvent is toluene; Hal is Br; ring A is a fused heterocyclic or heteroaryl ring; X is CN or COEt; and Ris Et.23. (canceled)24. (canceled)26. (canceled)27. (canceled)28. (canceled)30. (canceled)31. The method of claim 20 , wherein in step b) claim 20 , the second solvent is dimethylsulfoxide.33. The method of claim 20 , wherein in step c) claim 20 , the base is an inorganic base.34. The method of claim 20 , wherein in formula IID claim ...

Подробнее
12-12-2013 дата публикации

Opioid Receptor Ligands and Methods of Using and Making Same

Номер: US20130331408A1
Принадлежит: Trevena, Inc.

This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders. 175-. (canceled)77. The compound of claim 76 , or a pharmaceutically acceptable salt thereof claim 76 , wherein Dis an optionally substituted pyridyl.78. The compound of claim 76 , or a pharmaceutically acceptable salt thereof claim 76 , wherein Dis pyridyl.82. The compound of claim 80 , or a pharmaceutically acceptable salt thereof claim 80 , wherein one of R claim 80 , R claim 80 , and Ris H.83. The compound of claim 80 , or a pharmaceutically acceptable salt thereof claim 80 , wherein two of R claim 80 , R claim 80 , and Rare H.84. The compound of claim 81 , or a pharmaceutically acceptable salt thereof claim 81 , wherein Ris F.85. The compound of claim 83 , or a pharmaceutically acceptable salt thereof claim 83 , wherein Ris F claim 83 , and Rand Rare H.86. The compound of claim 76 , wherein the optionally substituted pyridyl is a halo substituted pyridyl.87. The compound of claim 86 , or a pharmaceutically acceptable salt thereof claim 86 , wherein the halo substituted pyridyl is a fluoro substituted pyridyl.90. A pharmaceutical composition comprising a compound of claim 76 , or pharmaceutically acceptable salt thereof claim 76 , and a pharmaceutically acceptable carrier.91. The pharmaceutical composition of further comprising at least one additional analgesic or non-opioid analgesic.92. The pharmaceutical composition of further comprising at least one anti-constipation agent.93. A pharmaceutical composition comprising a compound of claim 88 , or pharmaceutically acceptable salt thereof claim 88 , and a pharmaceutically acceptable carrier.94. The pharmaceutical composition of further comprising at least one additional analgesic or non-opioid analgesic.95. The pharmaceutical composition of further comprising at least one anti-constipation agent.97. A pharmaceutical composition comprising a ...

Подробнее
02-01-2014 дата публикации

4-(2-(6-SUBSTITUTED-HEXYLIDENE) HYDRAZINYL)BENZONITRILE AND PREPARATION THEREOF

Номер: US20140005395A1
Автор: Ronsheim Matthew
Принадлежит:

The present teachings provide a compound of Formula (I-B): 2. The compound of claim 1 , wherein Ris selected from halo claim 1 , cyano claim 1 , azido claim 1 , —OSOF claim 1 , —OSOCF claim 1 , —OSOCF claim 1 , —OSOPhCH claim 1 , —OSOPh claim 1 , and —OSOCH.3. The compound of claim 2 , wherein Ris selected from I claim 2 , Br claim 2 , and Cl.4. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently selected from H claim 1 , halo claim 1 , —CH claim 1 , —CFand —OCH.5. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently H.6. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently selected from H claim 1 , halo claim 1 , cyano claim 1 , —CH claim 1 , —CFand —OCH.7. The compound of claim 1 , wherein at least one R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris cyano.8. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently H; and Ris cyano.11. The process of claim 10 , wherein Ris selected from halo claim 10 , cyano claim 10 , azido claim 10 , —OSOF claim 10 , —OSOCF claim 10 , —OSOCF claim 10 , —OSOPhCH claim 10 , —OSOPh claim 10 , and —OSOCH.12. The process of claim 11 , wherein Ris selected from I claim 11 , Br claim 11 , and Cl.13. The process of claim 10 , wherein R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , and Rare each independently selected from H claim 10 , halo claim 10 , —CH claim 10 , —CFand —OCH.14. The process of claim 10 , wherein R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , R claim 10 , and Rare each independently H.15. The process of claim 10 , wherein at least one of R claim 10 , ...

Подробнее
09-01-2014 дата публикации

New positive allosteric modulators of nicotinic acetylcholine receptor

Номер: US20140010897A1
Принадлежит:

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor. 2. The compound according to claim 1 , wherein R6 is methyl.3. The compound according to claim 1 , wherein R6 is hydroxymethyl.4. The compound according to having a diastereomeric excess of at least 80%.5. The compound according to wherein the compound is selected from the group consisting of13: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((S)—-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-pyridin-3-yl}-ethyl)-amide;14: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((S)-1-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-pyridin-3-yl}-ethyl)-amide;19: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid {(S)-1-[6-(oxetan-3-yloxy)-pyridin-3-yl]-ethyl}-amide;43: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((R)-2-hydroxy-1-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-pyridin-3-yl}-ethyl)-amide;44: (1S,2S)—N-[(1R)-2-hydroxy-1-[6-[(3S)-tetrahydrofuran-3-yl]oxy-3-pyridyl]ethyl]-2-phenyl-cyclopropanecarboxamide;45: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid {(R)-2-hydroxy-1-[6-(tetrahydro-pyran-4-yloxy)-pyridin-3-yl]-ethyl}-amide;and pharmaceutically acceptable salts thereof.6. The compound according to claim 1 , wherein the compound is13: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((S)-1-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-pyridin-3-yl}-ethyl)-amide and pharmaceutically acceptable salts thereof.7. The compound according to claim 1 , wherein the compound is14: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((S)-1-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-pyridin-3-yl}-ethyl)-amide and pharmaceutically acceptable salts thereof.8. The compound according to claim 1 , wherein the compound is19: (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid {(S)-1-[6-(oxetan-3-yloxy)-pyridin-3-yl]-ethyl}-amide and pharmaceutically acceptable ...

Подробнее
09-01-2014 дата публикации

Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) Benzoic Acid

Номер: US20140011846A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. 123-. (canceled)24. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of 3-(6-(1-(2 ,2-difluorobenzo[d][1 ,3]-dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid characterized as Form I , wherein the mammal has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence.2532-. (canceled)33. The method of claim 24 , wherein the mammal has two copies of the defective gene.34. The method of claim 24 , wherein the Form I is characterized by one or more peaks at 15.2 to 15.6 degrees claim 24 , 16.1 to 16.5 degrees claim 24 , and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.35. The method of claim 34 , wherein the Form I is characterized by one or more peaks at 15.4 claim 34 , 16.3 claim 34 , and 14.5 degrees.36. The method of claim 34 , wherein the Form I is further characterized by a peak at 14.6 to 15.0 degrees.37. The method of claim 36 , wherein the Form I is further characterized by a peak at 14.8 degrees.38. The method of claim 36 , wherein the Form I is further characterized by a peak at 17.6 to 18.0 degrees.39. The method of claim 38 , wherein the Form I is further characterized by a peak at 17.8 degrees.40. The method of claim 38 , wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees.41. The method of claim 40 , wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees.42. The method of claim 41 , wherein the Form I is further characterized by a peak at 16.6 degrees.43. The method of claim 41 , wherein the Form I is further characterized ...

Подробнее
09-01-2014 дата публикации

CASPASE INHIBITORS AND USES THEREOF

Номер: US20140011847A1
Принадлежит:

This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6. 2. The inhibitor of claim 1 , wherein R4 is selected from the group consisting of H claim 1 , OH claim 1 , and CH3.3. The inhibitor of claim 1 , wherein Ris OH.4. The inhibitor of claim 1 , wherein said inhibitor preferentially inhibits caspase-3 and/or caspase-6 as compared to other caspases.5. The inhibitor of claim 1 , wherein Ar is a substituted aromatic or heteroaromatic.6. The inhibitor of claim 1 , wherein Ar is a halogen substituted aromatic or heteroaromatic.7. The inhibitor of claim 1 , wherein Ar is a fluorine substituted aromatic or heteroaromatic.8. The inhibitor of claim 1 , wherein Ar is 1 claim 1 ,2 claim 1 ,4 claim 1 ,5-tetrafluorophenyl.9. The inhibitor of claim 1 , wherein Ris H or methyl.10. The inhibitor of claim 9 , wherein Ris methyl.11. The inhibitor of claim 1 , wherein Ris cyclohexyl.18. The inhibitor of claim 1 , wherein said inhibitor is in a pharmaceutically acceptable carrier.20. The substrate of claim 19 , wherein R is an R group selected from the R groups listed in Table 3 claim 19 , Table 4 claim 19 , Table 5 claim 19 , Table 6 claim 19 , Table 7 claim 19 , and Table 8.21. The substrate of claim 19 , wherein Ris selected from the group consisting of CHCOOH claim 19 , COOH claim 19 , and OH.22. The substrate of claim 21 , wherein Ris COOH.23. The substrate of claim 19 , wherein Ris selected from the group consisting of CHCOOH claim 19 , COOH claim 19 , and OH.24. The substrate of claim 23 , wherein Ris COOH.25. The substrate of claim 19 , wherein Rand Rare independently selected from the group consisting of H claim 19 , OH claim 19 , and CH.26. The substrate according to claim 25 , wherein Rand Rare H.28. A method of inhibiting a caspase in a mammal claim 1 , said method comprising ...

Подробнее
16-01-2014 дата публикации

DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES

Номер: US20140018390A1
Автор: Tung Roger D.
Принадлежит: CONCERT PHARMACEUTICALS, INC.

The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents. 168.-. (canceled)70. The method of claim 69 , wherein up to 4 hydrogen atoms are replaced by deuterium.71. The method to claim 69 , wherein at least one of Yand Yis independently deuterium.72. The method of claim 69 , wherein both Yand Yare independently deuterium.74. The method of claim 73 , wherein all hydrogen atoms are present at their natural isotopic abundance.78. The method of claim 77 , wherein up to 4 hydrogen atoms are replaced by deuterium.79. The method to claim 77 , wherein at least one of Yand Yis independently deuterium.80. The method of claim 77 , wherein both Yand Yare independently deuterium.82. The method of claim 81 , wherein all hydrogen atoms are present at their natural isotopic abundance. This application is a continuation-in-part of U.S. patent application Ser. No. 11/498,334, filed Jul. 31, 2006, which claims benefit of U.S. provisional application 60/704,073, filed Jul. 29, 2005, the contents of each is incorporated by reference herein.The present invention relates to novel isotopologues of Compound 1, its acceptable acid with additional deuterium and C atoms in place of the normally abundant hydrogen and C, respectively addition salts, solvates, hydrates and polymorphs thereof, substituted with deuterium on the methylene ...

Подробнее
23-01-2014 дата публикации

Benzazepine Derivatives Useful as Vasopressin Antagonists

Номер: US20140024619A1
Принадлежит: OTSUKA PHARMACEUTICAL CO., LTD.

The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) 2. The compound according to claim 1 , wherein claim 1 , in formula (1) claim 1 , Ris a group of (1-5) claim 1 , or a salt thereof.3. The compound according to claim 2 , wherein claim 2 , in formula (1) claim 2 , Ris a —CO—Rwherein Ris an alkyl group claim 2 , or a salt thereof.4. (canceled)5. A pharmaceutical preparation comprising the benzazepine compound of or a pharmacologically acceptable salt thereof claim 1 , and a pharmacologically acceptable diluent and/or carrier.6. The pharmaceutical preparation according to which is used as a vasodilator claim 5 , hypotensive drug claim 5 , aquaretic agent claim 5 , or platelet aggregation inhibitor. The present invention relates to a novel benzazepine compound and a pharmaceutical preparation.Tolvaptan represented by the following formula (2) is a known compound, and is disclosed, for example, in U.S. Pat. No. 5,258,510 (Example 1199).Tolvaptan is known to be useful as a vasopressin antagonist having aquaretic efficacy (Circulation, 107, pp. 2690-2696 (2003)). However, because of its low water solubility, tolvaptan has problems in that it is poorly absorbed from the gastrointestinal tract, and its dosage form and administration route are limited. From the viewpoint of medical treatment, the development of a new drug that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects has been desired.An object of the present invention is to provide a novel benzazepine compound that has excellent properties, such as the maintenance of the blood level of tolvaptan for a long period of time enabling to provide the desired pharmaceutical effects.The present inventors carried out extensive research to ...

Подробнее
23-01-2014 дата публикации

Benzazepine Derivatives Useful as Vasopressin Antagonists

Номер: US20140024640A1
Принадлежит: OTSUKA PHARMACEUTICAL CO., LTD.

The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) 2. The compound according to claim 1 , wherein claim 1 , in formula (1) claim 1 , Ris a —CO—(CH)—COOH group wherein n is an integer of 1 to 4; or a salt thereof.3. (canceled)4. (canceled)5. A pharmaceutical preparation comprising the benzazepine compound of or a pharmacologically acceptable salt thereof claim 1 , and a pharmacologically acceptable diluent and/or carrier.6. The pharmaceutical preparation according to which is used as a vasodilator claim 5 , hypotensive drug claim 5 , aquaretic agent claim 5 , or platelet aggregation inhibitor. The present invention relates to a novel benzazepine compound and a pharmaceutical preparation.Tolvaptan represented by the following formula (2) is a known compound, and is disclosed, for example, in U.S. Pat. No. 5,258,510 (Example 1199).Tolvaptan is known to be useful as a vasopressin antagonist having aquaretic efficacy (Circulation, 107, pp. 2690-2696 (2003)). However, because of its low water solubility, tolvaptan has problems in that it is poorly absorbed from the gastrointestinal tract, and its dosage form and administration route are limited. From the viewpoint of medical treatment, the development of a new drug that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects has been desired.An object of the present invention is to provide a novel benzazepine compound that has excellent properties, such as the maintenance of the blood level of tolvaptan for a long period of time enabling to provide the desired pharmaceutical effects.The present inventors carried out extensive research to overcome the above problem, and as a result found that benzazepine compounds represented by general ...

Подробнее
23-01-2014 дата публикации

OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2

Номер: US20140024646A1
Принадлежит: Janssen Pharmaceutica NV

The present invention comprises compounds of Formula (I). 7. A pharmaceutical composition claim 1 , comprising a compound of and a pharmaceutically acceptable carrier.8. A pharmaceutical composition made by mixing a compound of and a pharmaceutically acceptable carrier.9. A process for making a pharmaceutical composition comprising mixing a compound of and a pharmaceutically acceptable carrier.10. A method for preventing claim 1 , treating or ameliorating a CCR2 mediated syndrome claim 1 , disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of .11. A method for preventing claim 1 , treating or ameliorating a CCDR2 mediated inflammatory syndrome claim 1 , disorder or disease wherein the syndrome claim 1 , disorder or disease is associated with elevated MCP-1 expression or MCP-1 overexpression claim 1 , or is an inflammatory condition that accompanies syndromes claim 1 , disorders or diseases associated with elevated MCP-1 expression or MCP-1 overexpression comprising administering to a subject in need thereof an effective amount of a compound of .12. A method of preventing claim 1 , treating or ameliorating a syndrome claim 1 , disorder or disease claim 1 , wherein said syndrome claim 1 , disorder or disease is selected from the group consisting of: chronic obstructive pulmonary disorder (COPD) claim 1 , ophthalmic disorders claim 1 , uveitis claim 1 , atherosclerosis claim 1 , rheumatoid arthritis claim 1 , psoriasis claim 1 , psoriatic arthritis claim 1 , atopic dermatitis claim 1 , multiple sclerosis claim 1 , Crohn's Disease claim 1 , ulcerative colitis claim 1 , nephritis claim 1 , organ allograft rejection claim 1 , fibroid lung claim 1 , renal insufficiency claim 1 , type-I diabetes claim 1 , type II diabetes claim 1 , diabetic complications claim 1 , diabetic nephropathy claim 1 , diabetic retinopathy claim 1 , diabetic retinitis claim 1 , diabetic microangiopathy claim 1 , overweight ...

Подробнее
23-01-2014 дата публикации

POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE

Номер: US20140024658A1
Принадлежит: Merck Patentgesellschaft

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. 155.-. (canceled)56. A compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride in its crystalline modification , wherein the compound is an anhydrate , hydrate , solvate or dihydrochloride.57. The compound of claim 56 , wherein the compound is an anhydrate in crystalline modification III.58. The compound of claim 56 , wherein the compound is an anhydrate in crystalline modification VII.59. The compound of claim 56 , wherein the compound is a solvate in crystalline modification XI.60. A pharmaceutical composition comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride anhydrate in its crystalline modification IV and one or more hydrated forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.61. A pharmaceutical composition according to claim 60 , wherein the composition comprises 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in its crystalline modification Form V.62. ...

Подробнее
06-02-2014 дата публикации

Squarylated Lactones Inhibitors for Bacterial Biofilm Formation

Номер: US20140039195A1
Принадлежит: SYRACUSE UNIVERSITY

A library of unnatural squarylated homoserine lactones (SHLs) and squarylated lactones that bear potential to modulate biofilm formation in Gram negative bacteria. At low concentrations (˜200 μM), these small molecules inhibit biofilm formation of . Moreover, these compounds are not toxic up to 300 μM and do not significantly attenuate growth. The SHLs have potential to disperse established biofilm and demonstrate an enhanced reduction (˜50%) of the maximum biofilm thickness by use of SHLs during biofilm growth. 2. The squarylated homoserine lactone of claim 1 , wherein said squarylated homoserine lactone is characterized by an ability to modulate quorum sensing.3. The squarylated homoserine lactone of claim 1 , wherein said squarylated homoserine lactone is characterized by an ability to inhibit biofilms.6. The squarylated homoserine lactone of claim 5 , wherein said squarylated homoserine lactone is characterized by an ability to modulate quorum sensing.7. The squarylated homoserine lactone of claim 5 , wherein said squarylated homoserine lactone is characterized by an ability to inhibit biofilms.8. A method of producing a squarylated homoserine lactone claim 5 , comprising the steps of:(a) subjecting 3,4-dibutoxy-cyclobut-3-ene-1,2-dione to Grignard/organolithium reagents to produce a 1,2 addition reaction; and(b) treating the product of step (a) with trifluoroacetic anhydride;(c) performing hydrolysis of the product of step (b) to produce a squarylated ester intermediate; and(d) treating said squarylated ester intermediate with and α-Amino-γ-butyrolactone to produce a squarylated homoserine lactone.10. The method of claim 9 , wherein said squarylated homoserine lactone is characterized by an ability to modulate quorum sensing.11. The method of claim 9 , wherein said squarylated homoserine lactone is characterized by an ability to inhibit biofilms.14. The method of claim 8 , wherein said squarylated homoserine lactone is characterized by an ability to modulate ...

Подробнее
20-02-2014 дата публикации

NOVEL SALTS AND POLYMORPHIC FORMS OF AFATINIB

Номер: US20140051713A1
Принадлежит:

Afatinib salts and crystalline forms thereof are described in the present application and processes for their preparation. Crystalline forms of Afatinib are also described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Afatinib salts and crystalline forms thereof or crystalline forms of Afatinib, methods of their preparation and the use thereof in the treatment of a patient in need thereof. 1. Difumarate salt of afatinib.2. The difumarate salt of afatinib of claim 1 , wherein the salt is crystalline.3. The difumarate salt of afatinib of claim 2 , wherein the crystalline difumarate salt of afatinib is crystalline afatinib difumarate salt form A.4. The difumarate salt of afatinib according to claim 3 , characterised by data selected from: an XRPD pattern showing characteristic peaks at 4.6±0.2 claim 3 , 24.8±0.2 and 26.1±0.2° 2-Theta claim 3 , an XRPD pattern substantially as depicted in ; and combination thereof.5. Dioxalate salt of afatinib.6. The dioxalate salt of afatinib of claim 5 , wherein the salt is crystalline.7. The dioxalate salt of afatinib of claim 6 , wherein the crystalline dioxalate salt of afatinib is crystalline afatinib dioxalate salt form A.8. The dioxalate salt of afatinib according to claim 7 , characterised by data selected from: an XRPD pattern showing characteristic peaks at 5.6±0.2 claim 7 , 23.5±0.2 and 25.3±0.2° 2-Theta claim 7 , an XRPD pattern substantially as depicted in ; and combination thereof.9. Dimesylate salt of afatinib.10. The dimesylate salt of afatinib of claim 9 , wherein the salt is crystalline.11. The dimesylate salt of afatinib of claim 10 , wherein the crystalline dimesylate salt of afatinib is crystalline afatinib dimesylate salt form A.12. The dimesylate salt of afatinib according to claim 11 , characterised by data selected from: an XRPD pattern showing characteristic peaks at 19.5±0.2 claim 11 , 25.3±0.2 and 25.7±0.2° 2-Theta ...

Подробнее
27-02-2014 дата публикации

Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof

Номер: US20140056818A1
Принадлежит: NATIONAL CENTRE FOR BIOLOGICAL SCIENCES

The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral DNA capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like FITC dextran within the cavity of a DNA polyhedron without any molecular recognition or chemical conjugation between host (DNA icosahedron) and cargo (like FITC Dextran). This DNA polyhedron is structurally well defined and shows high encapsulation efficiency. The present disclosure also relates to complex formed due to the encapsulation of neutral bioimaging agents within icosahedral DNA capsules.

Подробнее
27-02-2014 дата публикации

AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION

Номер: US20140057925A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD). 2. The amorphous form of vilazodone hydrochloride as claimed in claim 1 , wherein the vilazodone hydrochloride has the X-ray powder diffraction (XRD) pattern substantially as depicted in .3. The amorphous form of vilazodone hydrochloride as claimed in claim 1 , wherein the vilazodone hydrochloride has the thermal gravimetric analysis (TGA) substantially as depicted in .4. The amorphous form of vilazodone hydrochloride as claimed in having water content of from about 0.5% to about 10% wt/wt.5. The amorphous form of vilazodone hydrochloride as claimed in which is substantially free from residual organic solvents.6. The amorphous form of vilazodone hydrochloride as claimed in having a particle size in terms of d95 less than about 100 microns.7. A substantially pure amorphous form of vilazodone hydrochloride.8. The amorphous form of vilazodone hydrochloride as claimed in which is substantially free of crystalline forms of vilazodone hydrochloride.9. The amorphous form of vilazodone hydrochloride as claimed in having less than 10% of crystalline vilazodone hydrochloride.10. The amorphous form of vilazodone hydrochloride as claimed in having less than 5% of crystalline vilazodone hydrochloride.11. The amorphous form of vilazodone hydrochloride as claimed in having less than 1% of crystalline vilazodone hydrochloride.12. Storage stable amorphous form of vilazodone hydrochloride.13. The stable amorphous form of vilazodone hydrochloride as claimed in claim 12 , wherein the vilazodone hydrochloride has no change in the XRD pattern after storage for three months at 40° C. and 75% ...

Подробнее
13-03-2014 дата публикации

TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS

Номер: US20140073632A1
Принадлежит:

Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell. 158-. (canceled)6058. The method of claim , wherein L is —CH—.6158. The method of claim , wherein L is —CH—CH—.6258. The method of claim , wherein Z is substituted or unsubstituted aryl.6358. The method of claim , wherein the protein folding disorder is cystic fibrosis.65. The method of claim 63 , wherein the protein folding disorder is cystic fibrosis.68. The method of claim 65 , wherein the protein folding disorder is cystic fibrosis. This application claims priority to U.S. Provisional Application No. 61/486,929, filed May 17, 2011, which is incorporated herein by reference in its entirety.This invention was made with government support under Grant Nos. NIDDK R01 DK060065 and NIDDK Phase I SBIR DK084658 awarded by the National Institutes of Health. The government has certain rights in the invention.Cystic fibrosis is an example of a protein folding disorder. It is a hereditary disease caused by mutations in a gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR gene encodes a chloride channel that is expressed in multiple epithelial cell types. A common CFTR mutation, delF508, causes the failure of CFTR to traffic correctly to the plasma membrane because of protein misfolding. The delF508 mutation is estimated to account for 90% of mutant alleles. Because of its high degree of incidence in the cystic fibrosis population, delF508-CFTR is a prime target for cystic fibrosis ...

Подробнее
20-03-2014 дата публикации

Prodrugs of dhodh inhibitors and their uses

Номер: US20140080768A1
Принадлежит: Individual

The invention generally relates to Pro-Drugs of dihydroorotate dehydrogenase (DHODH) inhibitors and methods of use thereof. In certain embodiments, the invention provides a DHODH inhibitor compound including a cleavable functional group that increases bioavailability as compared to a form of the DHODH inhibitor without the functional group, rendering the former more suitable for therapeutic use.

Подробнее
20-03-2014 дата публикации

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Номер: US20140080826A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. 2. The compound of claim 1 , wherein Ris H or C1-C6 aliphatic.3. The compound of claim 1 , wherein Ris H.4. The compound of claim 1 , wherein two adjacent Rtogether with the atoms to which they are attached form an optionally substituted carbocyclic or an optionally substituted heterocycle.5. The compound of claim 1 , wherein two adjacent Rtogether with the atoms to which they are attached form an optionally substituted heterocycle.11. The compound of claim 1 , wherein 1 Ris halo.12. The compound of claim 1 , wherein 1 Ris F.13. The compound of claim 1 , wherein R′and an adjacent Rtogether with the atoms to which they are attached form an optionally substituted heterocycle.14. The compound of claim 1 , wherein R′and an adjacent Rtogether with the atoms to which they are attached form an optionally substituted 3 to 7 membered heterocycle in which one or more of the ring atoms is N claim 1 , O claim 1 , S claim 1 , or combination thereof.15. The compound of claim 1 , wherein R′and an adjacent Rtogether with the atoms to which they are attached form an optionally substituted 7 membered heterocycle in which one or more of the ring atoms is N claim 1 , O claim 1 , S claim 1 , or combination thereof.16. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier or adjuvant.17. The composition of claim 16 , wherein the composition comprises an additional agent selected from a mucolytic agent claim 16 , bronchodialator claim 16 , an anti-biotic claim 16 , an anti-infective agent claim 16 , an anti-inflammatory agent claim 16 , CFTR modulator claim 16 , or a ...

Подробнее
03-04-2014 дата публикации

NEW INTERMEDIATES AND PROCESSES FOR PREPARING TICAGRELOR

Номер: US20140094604A1
Принадлежит: TEVA PHARMACEUTICAL INDUSTRIES LTD.

The present invention is related to new intermediates and processes for preparing Ticagrelor disclosed in this patent application. 2. The process according to claim 1 , wherein the compound of Formula X is N-(4-chloro-6-(((3aS claim 1 ,4R claim 1 ,6S claim 1 ,6aR)-6-(2-hydroxyethoxy)-2 claim 1 ,2-dimethyl tetrahydro-3aH-cyclopenta-[d][1 claim 1 ,3]dioxol-4-yl)amino)-2-(propylthio)pyrimidin-5-yl)formamide claim 1 , or N-(4-chloro-6-((3aR claim 1 ,4S claim 1 ,6R claim 1 ,6aS)-4-(2-hydroxyethoxy)tetrahydro-3aH-spiro[cyclopenta-[d][1 claim 1 ,3]dioxole-2 claim 1 ,1′-cyclopentane]-6-ylamino)-2-(propylthio)pyrimidin-5-yl)formamide.4. The process of claim 3 , wherein X is a halogen.8. A compound according to claim 7 , wherein Ris selected from benzyloxycarbonyl claim 7 , optionally substituted at the 4-position with —C-Calkoxy; benzyloxy claim 7 , optionally substituted with 1 or 2 substituents independently selected from —C-Calkoxy; —C-Calkoxycarbonyl claim 7 , —C-Carylalkyl claim 7 , optionally substituted benzoyl claim 7 , —C-Calkanoyl claim 7 , —C-Calkylsulfonyl claim 7 , optionally alkyl substituted phenylsulfonyl claim 7 , C-Calkylcarbamoyl claim 7 , phenylcarbamoyl claim 7 , and optionally substituted benzyl carbamoyl.12. A compound according to claim 11 , wherein the compound is N-(4 claim 11 ,6-dichloro-2-(propylthio)pyrimidin-5-yl)formamide.14. The process according to claim 13 , wherein X is a halogen.17. A compound according to claim 16 , wherein Ris —H and X is a halogen. This patent application claims the benefits of U.S. Provisional Patent Application Nos. 61/472,412 filed Apr. 6, 2011 and 61/490,371 filed May 26, 2011, the disclosures of which are incorporated by reference herein.The invention encompasses improved processes for preparing Ticagrelor and new intermediates useful for manufacturing Ticagrelor.Ticagrelor, (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]-amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5,d]pyrimidine-3-yl]-5-(2- ...

Подробнее
05-01-2017 дата публикации

AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS

Номер: US20170001968A1

In some aspects, the present invention provides compounds of the formula (IV), wherein the variables are as defined herein, which may be used as inhibitors of histone demethylase or spermine oxidase. Also provided herein are pharmaceutical compositions of the compounds and methods using the compounds in the treatment of diseases such as cancer and cardiovascular disease. 3. The compound of either or , wherein Ris hydrogen.4. The compound of claim 3 , wherein Ris halo.5. The compound of claim 4 , wherein Ris —Br or —Cl.6. The compound of claim 5 , wherein Ris —Cl.7. The compound according to any one of - claim 5 , wherein Yis alkylaminodiyl.8. The compound of claim 7 , wherein Yis —CHNH— or —NHCH—.9. The compound according to any one of - claim 7 , wherein Xis —O— claim 7 , —S— claim 7 , or —NH—.10. The compound of claim 9 , wherein Xis —O—.11. The compound of claim 9 , wherein Xis —S—.12. The compound according to any one of - claim 9 , wherein Ris alkylor substituted alkyl.13. The compound of claim 12 , wherein Ris alkyl.14. The compound of claim 13 , wherein Ris methyl.15. The compound according to any one of - claim 13 , wherein Ris arylor substituted aryl.16. The compound of claim 15 , wherein Ris aryl.17. The compound of claim 16 , wherein Ris 1-napthyl claim 16 , 2-napthyl claim 16 , 4 claim 16 ,4′-diphenyl claim 16 , 4-methylphenyl claim 16 , 3 claim 16 ,5-dimethylphenyl claim 16 , 4-t-butylphenyl claim 16 , 2-isopropyl-4-methylphenyl claim 16 , 2-methylphenyl claim 16 , or 2 claim 16 ,3-dimethylphenyl.18. The compound of claim 15 , wherein Ris substituted aryl.20. The compound according to any one of - claim 15 , wherein Ris heteroarylor substituted heteroaryl.21. The compound of claim 20 , wherein Ris heteroaryl.22. The compound of claim 21 , wherein Ris indolyl.25. A pharmaceutical composition comprising a compound of - and an excipient.26. The pharmaceutical composition of claim 25 , wherein the pharmaceutical composition is formulated for oral claim 25 , ...

Подробнее
04-01-2018 дата публикации

S-triazolyl alpha-mercapto acetanilides as inhibitors of hiv reverse transcriptase

Номер: US20180002296A1
Принадлежит: Ardea Biociences Inc

A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO 2 H, CONR 2 , SO 3 H, or SO 2 NR 2 . The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

Подробнее
05-01-2017 дата публикации

NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA

Номер: US20170002040A1
Принадлежит:

The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure. 1. A pharmaceutical composition comprising a benzothiadiazine or chroman derivative disposed in an ophthalmically acceptable aqueous carrier.4. A unit dose container comprising the pharmaceutical composition according to .5. The unit dose container according to claim 4 , wherein the unit dose container is an eye drop dispenser.8. A pharmaceutical composition of claim 6 , wherein the benzothiadiazine or chroman derivative is comprise a 3S claim 6 ,4R stereo chemistry or a 3R claim 6 ,4S stereo chemistry.9. The pharmaceutical composition of claim 6 , wherein the compound is administered by topical application to the eye or administered by injection into the anterior chamber.10. The pharmaceutical composition of claim 6 , wherein the compound is administered using an ocular insert.11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is a prodrug that is activated by removing one or more groups from the pharmaceutical composition.13. A composition as in claim 12 , wherein the R2 is a 2-pyrrolidinone group; R4 and R5 are —CH; and R6 claim 12 , R7 and R8 are —H. The present invention relates generally to benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives and methods for treating glaucoma and reducing intraocular pressure. It also relates to a process for their preparation and pharmaceutical compositions in which they are present.Without limiting the scope of the ...

Подробнее
03-01-2019 дата публикации

CRYSTALLINE FORMS OF VILAZODONE HYDROCHLORIDE AND VILAZODONE FREE BASE

Номер: US20190002444A1
Принадлежит:

The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base. 178-. (canceled)79. Crystalline form of vilazodone hydrochloride wherein the crystalline form is selected from a group of:form B of vilazodone hydrochloride characterized by powder X-ray diffraction (PXRD) pattern having peaks at about 7.10, 14.96, 17.31 and 21.64±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 7.10, 14.96, 17.31 19.63, 21.64, 22.40, 22.99, 25.91 and 26.72±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 7.10, 12.10, 12.66, 14.96, 17.31 19.63, 21.64, 22.40, 22.99, 25.91 and 26.72±0.2 degrees 2θ;form C of vilazodone hydrochloride characterized by powder X-ray diffraction (PXRD) pattern having peaks at about 10.50, 14.20 and 20.20±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 9.06, 10.50, 14.20 and 20.20±0.2 degrees 2θ;form D of vilazodone hydrochloride characterized by powder X-ray diffraction (PXRD) pattern having peaks at about 13.39, 13.67, 16.00, 21.22 and 24.61±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 5.53, 9.60, 10.54, 11.09, 13.39, 13.67, 16.00, 21.22 and 24.61±0.2 degrees 2θ;form E of vilazodone hydrochloride characterized by powder X-ray diffraction (PXRD) pattern having peaks at about 10.62, 16.18 and 21.42±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 5.55, 9.54, 10.62, 11.06, 16.18 and 21.42±0.2 degrees 2θ;form F of vilazodone hydrochloride characterized by powder X-ray diffraction (PXRD) pattern having peaks at about 13.45, 13.73, 21.24 and 24.85±0.2 degrees 2θ; or powder X-ray diffraction (PXRD) pattern having peaks at about 10.65, 11.07 ...

Подробнее
04-01-2018 дата публикации

MACROCYCLIC PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY

Номер: US20180002319A1
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris selected from the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.4. (canceled)5. The compound according to claim 2 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.6. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.7. The compound according to claim 6 , wherein Ris selected from the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.8. (canceled)9. The compound according to claim 6 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.10. The compound according to claim 1 , wherein X is hydrogen and Y is Q.11. The compound according to claim 10 , wherein Ris alkoxy.12. The compound according to claim 11 , wherein Ris hydrogen.13. The compound according to claim 12 , wherein Ris selected from the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. (canceled)15. The compound according to claim 12 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.16. The compound according to claim 11 , ...

Подробнее
04-01-2018 дата публикации

USE OF MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20180002320A1
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A composition according to claim 1 , wherein X is hydrogen and Y is Q.3. A composition according to claim 2 , wherein Ris alkoxy.4. A composition according to claim 3 , wherein Ris hydrogen.5. A composition according to claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. (canceled)7. A composition according to claim 4 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.8. A composition according to claim 3 , wherein Ris selected from the group consisting of —C(O)Rand —CHOC(O)R.9. A composition according to claim 8 , wherein Ris alkyl claim 8 , optionally substituted with 0 claim 8 , 1 claim 8 , or multiple R.10. A composition according to claim 9 , wherein Ris selected from the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.11. (canceled)12. A composition according to claim 9 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.13. A composition according to claim 12 , wherein Ris selected from the group consisting of —CH claim 12 , —CH(CH) claim 12 , and —CHOCHCH.14. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.15. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.16. (canceled)17. A ...

Подробнее
07-01-2021 дата публикации

CATALYSTS AND METHODS FOR ENANTIOSELECIVE CONJUGATE ADDITION OF AMINES TO UNSATURATED ELECTROPHILES

Номер: US20210002221A1
Автор: Scheidt Karl A., Uno Brice
Принадлежит:

Disclosed are complexes and methods of using the complexes as catalysts for addition of amines to unsaturated electrophiles, as well as novel compounds produced by the disclosed complexes and methods. The disclosed methods may utilize the disclosed complexes as catalysts for adding unprotected primary amines and secondary amines to unsaturated electrophiles in an enantioselective manner to produce novel compounds which may include amino substituted succinimide compounds. 2. The complex of claim 1 , wherein R is selected from the group consisting of naphthalene claim 1 , phenanthrene claim 1 , SiPh claim 1 , and CF.3. The complex of claim 1 , wherein R is selected from the group consisting of 1-naphthalene claim 1 , 2-naphthalene claim 1 , 1-phenanthrene claim 1 , 2-phenanthrene claim 1 , and 9-phenanthrene.4. The complex of claim 1 , wherein R is 9-phenanthrene.5. The complex of claim 1 , wherein M is an alkaline earth metal.6. The complex of claim 1 , wherein M is Ca.8. The complex of claim 7 , wherein R is selected from the group consisting of naphthalene claim 7 , phenanthrene claim 7 , SiPh claim 7 , and CF.9. The complex of claim 7 , wherein R is selected from the group consisting of 1-naphthalene claim 7 , 2-naphthalene claim 7 , 1-phenanthrene claim 7 , 2-phenanthrene claim 7 , and 9-phenanthrene.10. The complex of claim 7 , wherein R is 9-phenanthrene.11. The complex of claim 7 , wherein M is an alkaline earth metal.12. The complex of claim 7 , wherein M is Ca.13. A method for conjugating an amine to an unsaturated electrophile claim 7 , the method comprising reacting the amine and the unsaturated electrophile in the presence of the complex of 1 as a catalyst in a reaction mixture claim 7 , the method optionally including recycling the complex for a subsequent reaction claim 7 , optionally wherein the amine is unprotected.14. A method for conjugating an amine to an unsaturated electrophile claim 7 , the method comprising reacting the amine and the ...

Подробнее
07-01-2021 дата публикации

Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors

Номер: US20210002264A1
Принадлежит:

In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention. 3. The compound of claim 2 , wherein Ris selected from the group consisting of phenyl and naphthyl.6. The compound of claim 5 , wherein Ris selected from the group consisting of phenyl and naphthyl.7. The compound of claim 5 , wherein Ris methyl.10. The compound of claim 9 , wherein Ris selected from the group consisting of methylphenyl claim 9 , methoxyphenyl claim 9 , fluorophenyl claim 9 , ethylnapthyl claim 9 , cyclopropylnaphthyl claim 9 , methylbiphenyl claim 9 , ethoxybiphenyl claim 9 , and N-morpholinopropoxybiphenyl.11. The compound of claim 9 , wherein X is fluorine.13. A pharmaceutical composition comprising the compound of and at least one pharmaceutically acceptable excipient.14. A method of treating or ameliorating an inflammatory disease claim 1 , a neurological disorder claim 1 , or cancer in a subject in need thereof claim 1 , the method comprising administering to the subject an effective amount of the compound of .15. The method of claim 14 , wherein the inflammatory disease is rheumatoid arthritis claim 14 , Crohn's disease claim 14 , or inflammatory bowel syndrome.16. The method of claim 14 , wherein the neurological disorder is schizophrenia.17. The method of claim 14 , wherein the cancer is colorectal claim 14 , lung claim 14 , breast claim 14 , or prostate.18. A method of inhibiting macrophage migration inhibitory factor in a subject in need thereof claim 1 , the method comprising administering to the subject an effective amount of the compound of .19. A method of treating or ameliorating a disease or disorder associated with upregulated and/or dysregulated macrophage migration inhibitory factor expression in a subject in need thereof claim 1 , the method comprising administering ...

Подробнее
01-01-2015 дата публикации

POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Номер: US20150005282A1
Принадлежит:

Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description. 2. The compound of formula (I) claim 1 , or a tautomer claim 1 , mesomer claim 1 , racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , or mixture thereof claim 1 , or a pharmaceutically acceptable salt thereof according to claim 1 , wherein ring B is aryl.4. The compound of formula (I) claim 1 , or a tautomer claim 1 , mesomer claim 1 , racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , or mixture thereof claim 1 , or a pharmaceutically acceptable salt thereof according to claim 1 , wherein L is —O—.5. The compound of formula (I) claim 1 , or a tautomer claim 1 , mesomer claim 1 , racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , or mixture thereof claim 1 , or a pharmaceutically acceptable salt thereof according to claim 1 , wherein Ris selected from the group consisting of alkyl claim 1 , halogen claim 1 , and hydroxyalkyl.6. The compound of formula (I) claim 1 , or a tautomer claim 1 , mesomer claim 1 , racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , or mixture thereof claim 1 , or a pharmaceutically acceptable salt thereof according to claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , alkyl claim 1 , and halogen.7. The compound of formula (I) claim 1 , or a tautomer claim 1 , mesomer claim 1 , racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , or mixture thereof claim 1 , or a pharmaceutically acceptable salt thereof according to claim 1 , wherein Ris hydrogen.8. The compound of formula (I) claim 1 , or a tautomer claim 1 , ...

Подробнее
01-01-2015 дата публикации

FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Номер: US20150005286A1
Принадлежит:

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. 119-. (canceled)21. The compound of claim 20 , or a pharmaceutically acceptable salt claim 20 , or solvate thereof claim 20 , wherein:{'sup': '1', 'sub': 1', '6, 'Ris H or C-Calkyl.'}22. The compound of claim 21 , or a pharmaceutically acceptable salt claim 21 , or solvate thereof claim 21 , wherein:{'sup': '5', 'Ris —OH;'}{'sup': 10', '12', '12, 'sub': 2', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'each Ris independently selected from H, halogen, —CN, —OH, —S(═O)R, —S(═O)R, C-Calkyl, C-C-fluoroalkyl, C-C-fluoroalkoxy, C-Calkoxy, and C-Cheteroalkyl; and'}{'sup': '11', 'Ris H.'}23. The compound of claim 22 , or a pharmaceutically acceptable salt claim 22 , or solvate thereof claim 22 , wherein:{'sup': '1', 'sub': '3', 'Ris H, or —CH.'}25. The compound of claim 24 , or a pharmaceutically acceptable salt claim 24 , or solvate thereof claim 24 , wherein:{'sup': '5', 'Ris —OH;'}{'sup': '6', 'each Ris independently selected from H and halogen;'}{'sup': '10', 'each Ris independently selected from H and halogen; and'}{'sup': '11', 'Ris H.'}30. A pharmaceutical composition comprising a compound of claim 20 , or a pharmaceutically acceptable salt claim 20 , or solvate thereof claim 20 , and at least one pharmaceutically acceptable inactive ingredient.31. The pharmaceutical composition of claim 30 , wherein the pharmaceutical composition is formulated for intravenous injection claim 30 , subcutaneous injection claim 30 , oral administration claim 30 , or topical administration.32. The pharmaceutical composition of claim 30 , wherein the pharmaceutical composition is a tablet claim 30 , a pill ...

Подробнее
01-01-2015 дата публикации

Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-lndol-5-yl)-Cyclopropanecarboxamide

Номер: US20150005344A1
Принадлежит:

The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith. 170-. (canceled)71. A method of treating a CFTR mediated disease in a subject comprising administering to the subject an effective amount of (R)-1-(2 ,2-Difluorobenzo[d][1 ,3]dioxol-5-yl)-N-(1-(2 ,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide crystalline Form A characterized by one or more peaks at 19.3 to 19.7 degrees , 21.5 to 21.9 degrees , 16.9 to 17.3 , and 20.2 to 20.6 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation , wherein the CFTR mediated disease is selected from male infertility and pancreatic insufficiency.7280-. (canceled)81. The method of claim 71 , wherein the (R)-1-(2 claim 71 ,2-Difluorobenzo[d][1 claim 71 ,3]dioxol-5-yl)-N-(1-(2 claim 71 ,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide crystalline Form A is characterized by one or more peaks at about 19.5 claim 71 , 21.7 claim 71 , and 17.1 degrees.82. The method of claim 71 , wherein the (R)-1-(2 claim 71 ,2-Difluorobenzo[d][1 claim 71 ,3]dioxol-5-yl)-N-(1-(2 claim 71 ,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide crystalline Form A is characterized by a peak at 20.2 to 20.6 degrees.83. The method of claim 71 , wherein the (R)-1-(2 claim 71 ,2-Difluorobenzo[d][1 claim 71 ,3]dioxol-5-yl)-N-(1-(2 claim 71 ,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide crystalline Form A is characterized by a peak at about 20.4 degrees.84. The method of claim 71 , wherein the (R)-1-(2 claim 71 ,2-Difluorobenzo[d][1 claim 71 ,3]dioxol-5- ...

Подробнее
01-01-2015 дата публикации

PKC-EPSILON INHIBITORS

Номер: US20150005349A1
Принадлежит:

The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R, R, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. 2. The compound of claim 1 , wherein Cy is selected from the group consisting of C-Ccycloalkyl and heterocyclyl.3. The compound of claim 1 , wherein Cy is selected from the group consisting of cyclohexyl and adamantyl.4. The compound of claim 1 , wherein Cy is selected from the group consisting of piperidinyl and piperazinyl.5. The compound of claim 1 , wherein Ar is selected from the group consisting of 1H-pyrrolo[2 claim 1 ,3-b]pyridin-4-yl and pyridin-4-yl.15. A pharmaceutical or a veterinary composition comprising a compound of .16. A pharmaceutical or veterinary composition according to further comprising at least one carrier claim 15 , excipient or diluent acceptable for pharmaceutical and/or veterinary purposes.17. A method for treating a patient suffering from substance abuse and/or substance dependence claim 1 , which method comprises administering an effective amount of a compound of to said patient.18. A method for treating a patient suffering from depression claim 1 , which method comprises administering an effective amount of a compound of to said patient.19. A method for inhibiting the activity of at least one kinase claim 1 , in vitro or in vivo using a compound according to claim 1 , or a composition comprising such a compound.20. The method of claim 19 , wherein the at least one kinase is selected from PKC epsilon claim 19 , PKC theta claim 19 , and ROCK. This application is a divisional application of U.S. patent application Ser. No. 13/340 ...

Подробнее